

# THE ROLE OF THE RHO-ROCK PATHWAY IN THE REGULATION OF MICTURITION

PhD thesis

**Helga Balla PharmD**

Semmelweis University Doctoral School

Theoretical and Translational Medicine Division



Supervisor: Zoltán Benyó, MD, D.Sc

Official reviewers: Norbert Szentandrassy, MD, Ph.D  
Márton Keszthelyi, MD, Ph.D

Head of the Complex Examination Committee:  
Péter Sótónyi, MD, D.Sc

Members of the Complex Examination Committee:  
Tamás Radovits, MD, Ph.D  
Charaf Hassan, D.Sc

Budapest  
2024

## Table of Contents

ABBREVIATIONS .....	3
1. INTRODUCTION .....	5
1.1. Regulation of micturition.....	5
1.2. Adrenergic mechanisms of the urinary bladder .....	5
1.3. Cholinergic neurotransmission regulating voiding mechanism.....	6
1.4. G protein-coupled signaling pathways .....	9
1.5. Intracellular signaling of smooth muscle contraction.....	10
a) Calcium-dependent pathway of smooth muscle contraction .....	10
b) Calcium sensitizing pathway of detrusor contraction.....	11
1.6. ROCK as a pharmacological treatment target for the disorders of the urinary bladder .....	13
2. OBJECTIVES .....	15
3. METHODS .....	16
3.1. Animals.....	16
3.2. Human urinary bladder tissues .....	16
3.3. Preparation of smooth muscle strips.....	17
3.4. Myography, determination of concentration-response curves.....	18
3.5. Quantification of RhoA activation.....	21
3.6. Evaluation of gene expression .....	21
3.7. Drugs and solutions .....	23
3.8. Data analysis and statistics .....	24
4. RESULTS .....	25
4.1. The Rho–ROCK pathway has a major role in the regulation of carbamoylcholine (CCh)-induced smooth muscle contraction in murine and human urinary bladder .....	25

4.2.	The role of the M <sub>2</sub> and M <sub>3</sub> receptors in the detrusor muscle contraction and RhoA activation induced by carbamoylcholine (CCh).....	28
4.3.	Inhibitory effect of pertussis toxin (PTX) on carbamoylcholine (CCh)-induced urinary bladder smooth muscle contraction and RhoA activation.....	33
4.4.	G $\alpha_{q/11}$ -coupled signaling pathway plays a key role in urinary bladder contractions but not in RhoA activation induced by carbamoylcholine (CCh)..	34
5.	DISCUSSION.....	36
6.	CONCLUSION.....	41
7.	SUMMARY.....	42
8.	REFERENCES .....	43
9.	BIBLIOGRAPHY OF THE CANDIDATE’S PUBLICATIONS.....	63
10.	ACKNOWLEDGMENTS .....	64

## Abbreviations

ACh – acetylcholine

ATP – adenosine triphosphate

*B2m* – beta-2 microglobulin

CaM – calmodulin

cAMP – cyclic adenosine monophosphate

CCh – carbamoylcholine

cDNA – complementary deoxyribonucleic acid

*Chrm1* – M<sub>1</sub> receptor gene

*Chrm2* – M<sub>2</sub> receptor gene

*Chrm3* – M<sub>3</sub> receptor gene

*Chrm4* – M<sub>4</sub> receptor gene

*Chrm5* – M<sub>5</sub> receptor gene

Cre-ERT2 – fusion protein of Cre recombinase with mutated human estrogen receptor ligand binding domain

CTRL – control

G proteins – heterotrimeric guanine nucleotide-binding regulatory proteins

GAP – GTPase-activating protein

GDI – guanine nucleotide dissociation inhibitor

GDP – guanosine diphosphate

GEF – guanine nucleotide exchange factor

GPCR – G protein-coupled receptor

GTP – guanosine-5'-triphosphate

IP<sub>3</sub> – inositol 1,4,5-trisphosphate

IP<sub>3</sub>R – inositol trisphosphate receptor

KO – knockout

LUT – lower urinary tract

mAChR – muscarinic acetylcholine receptor

MLC – myosin light-chain

MLCK – myosin light-chain kinase

MLCP – myosin light-chain phosphatase

mRNA – messenger ribonucleic acid

NA – norepinephrine

OAB – overactive bladder syndrome

PKC – protein kinase C

PLC – phospholipase C

PTX – pertussis toxin

qPCR – quantitative polymerase chain reaction

RBD – Rho binding domain

RNA – ribonucleic acid

ROCK – Rho-associated coiled-coil-containing protein kinase

*Rock1* – Rho-associated coiled-coil-containing protein kinase 1 gene

*Rock2* – Rho-associated coiled-coil-containing protein kinase 2 gene

RyR – ryanodine receptor

SMC – smooth muscle cell

SMMHC – smooth muscle myosin heavy chain

SR – sarcoplasmic reticulum

UB – urinary bladder

UBSM – urinary bladder smooth muscle

WT – wild type

$\alpha_1$ -AR –  $\alpha_1$  adrenergic receptor

$\alpha_2$ -AR –  $\alpha_2$  adrenergic receptor

$\beta_3$ -AR –  $\beta_3$  adrenergic receptor

## **1. Introduction**

### **1.1. Regulation of micturition**

The urinary bladder (UB) is a highly flexible, hollow smooth muscle organ with two main functions: storage of urine and expulsion. It features a layered smooth muscle structure with urothelium and lamina propria. The storage space of the urine during the filling phase is maintained by low intravesical pressure sustained by the relaxed urinary bladder smooth muscle (UBSM), especially the detrusor muscle. At the time of voiding the detrusor muscle rapidly contracts which attracts the increase of the intravesical pressure and afterwards expulsion of the urine can occur simultaneously with the opening of the external urethral sphincter. The functions of the urothelium, afferent nerves, spinal and hypothalamic centers, efferent pathways, detrusor and sphincter muscles have to be coordinated during both the storage and voiding phase (1). Disturbances of the filling phase may result in lower urinary tract (LUT) symptoms, like urgency, frequency, urge incontinence and overactive bladder syndrome (OAB). Moreover, the dysregulation of the voiding phase may result in symptoms of hesitancy, weak urine stream, incomplete bladder emptying and post-micturition dribble (2).

Integration of these functions is mediated by a complex neural control system. Most importantly, the bladder is under the control of the parasympathetic and the sympathetic nervous system (3, 4).

### **1.2. Adrenergic mechanisms of the urinary bladder**

The sympathetic nervous system plays the predominant role in the physiological regulation of the UB during the filling phase, since sympathetic nerves activate smooth muscle contraction in the urethra and the bladder neck along with the relaxation of the detrusor muscle (5). Moreover, the inhibition of the micturition stimulating pathways and the activation of inhibitory pathways also contribute to the low and relatively constant bladder pressure (5, 6). The contraction of the urethra and bladder neck and the relaxation of the detrusor muscle are mediated by different adrenergic receptors as a part of the sympathetic system. It has been demonstrated that  $\alpha_1$  and  $\beta_3$  adrenergic receptors ( $\alpha_1$ -ARs,  $\beta_3$ -ARs) are expressed in the human UB. However, the low density of the  $\alpha_1$ -ARs has also been confirmed at messenger ribonucleic acid (mRNA) and

protein levels suggesting the predominant role of  $\beta_3$ -ARs in the regulation of detrusor muscle during the storage phase (7). In contrast, the  $\alpha_1$ -ARs are important in maintaining outlet resistance (8). The activation of the sympathetic innervation causes the release of norepinephrine (NA) to activate the adrenergic receptors. Therefore, NA causes contraction in the urethral and bladder neck smooth muscle via  $\alpha_1$ -ARs in concert with the activation of the  $\beta_3$ -ARs inducing detrusor muscle relaxation (9). Activation of  $\beta_3$ -ARs results in elevation of cyclic adenosine monophosphate (cAMP) production within the cells resulting in relaxation of the UBSM. Moreover, it has been proposed that the  $\beta_3$ -ARs can interact with  $K^+$  channels as well, suggesting a cAMP-independent effect of the  $\beta_3$ -ARs on the detrusor muscle relaxation (10, 11).

Previously,  $\alpha_2$  adrenergic receptors ( $\alpha_2$ -ARs) were considered to be the major presynaptic regulators of the release of NA as part of a negative feedback loop. Recently, their role have been reported at postsynaptic locations to regulate the effects induced by catecholamines released from sympathetic nerve terminals (12). However, according to Michel *et al.* (2006), there is no study reporting the expression of  $\alpha_2$ -ARs mRNA in the bladder tissue (7), it has been demonstrated that  $\alpha_2$ -ARs can be detected in rabbit, pig and human UB at the protein level (13-16).  $\alpha_2$ -ARs regulate the activity of the parasympathetic nerves triggering bladder contraction in cats and rabbits by the inhibition of neurotransmitter release from the parasympathetic ganglion (17-20). These findings support the key function of adrenoreceptors, the promotion of the urinary continence. Furthermore, the reduction of volume-induced bladder contractions has been established *in vivo* in anesthetized rats by the stimulation of  $\alpha_2$ -ARs (18, 21).

It has been suggested that the contribution of the  $\alpha_1$ -ARs to the regulation of the UBSM may change under pathophysiological conditions related to detrusor overactivity (22, 23). In addition, the imbalance between  $\alpha_1$ -ARs and  $\beta_3$ -ARs functions has been suggested in bladder outflow obstruction (24, 25).

### **1.3. Cholinergic neurotransmission regulating voiding mechanism**

Under physiological conditions, parasympathetic cholinergic neurotransmission seems to play the dominant role in the regulation of the UB compared to that of the adrenergic mechanisms (1). The parasympathetic nervous system is the key regulator for the UBSM contraction with the aim of urine expulsion at the end of the filling phase.

When the volume of urine reaches a critical threshold within the bladder, contractions of UBSM cells will occur in concert with the opening of the bladder neck and relaxation of the external urethral sphincter resulting in the expulsion of the urine (5). The main neurotransmitter of the parasympathetic neurons is acetylcholine (ACh) (26) which transmits its effects via muscarinic acetylcholine receptors (mAChRs). Moreover, it has been demonstrated that the release of adenosine triphosphate (ATP) also occurs as a co-transmitter after parasympathetic stimulation in some species indicating that the two neurotransmitters maintain the normal bladder function simultaneously (26, 27).

It has been revealed that the mAChRs comprise five subtypes, M<sub>1</sub>-M<sub>5</sub> (28). Although they show a high degree of homology, their function in physiological responses and G protein binding affinity differ significantly (29). According to the literature, M<sub>1</sub>, M<sub>3</sub> and M<sub>5</sub> receptors prefer to couple to G<sub>q/11</sub> proteins, whereas M<sub>2</sub> and M<sub>4</sub> receptors show selectivity to G<sub>i/o</sub> proteins (28, 30-32). To date, it has been demonstrated that the M<sub>1</sub> receptors enhance, whereas M<sub>2</sub> receptors inhibit the release of ACh prejunctionally in rat and rabbit bladders (27, 33). Moreover, it has been suggested that the release of ACh is inhibited by M<sub>4</sub> receptors in both human and murine UBs (34, 35).

It has been established that the mAChRs are expressed in the bladder urothelium and the suburothelial area (36-39). The entire amount of the M<sub>1</sub> receptors is located in basal cells of the urothelial layer (40), whereas M<sub>2</sub> and M<sub>3</sub> receptor expressions were described in detrusor muscle, nerve fibers, urothelium and also in myofibroblast-like cells within the suburothelial layer in the human UB (41). There is conflicting literature data about the expression of the muscarinic receptors in the detrusor muscle. Abrams *et al.* (2006) and Sigala *et al.* (2002) suggested that all mAChR subtypes are expressed in the UBSM (42, 43). However, in other studies, no evidence was demonstrated of the presence of the M<sub>5</sub> receptors at mRNA and protein levels in the detrusor muscle (44-46). Furthermore, Bahadory *et al.* (2013) reported that M<sub>5</sub> receptors are expressed in the porcine and human UB (47), but not necessarily in the UBSM. On the other hand, several studies in human, rat, guinea pig and rabbit bladders have ambiguously demonstrated that only M<sub>2</sub> and M<sub>3</sub> receptors are expressed in the detrusor (27, 45) and principally mediate UBSM contractions, which observation is supported by the predominance of mRNAs encoding M<sub>2</sub> and M<sub>3</sub> receptors in the human UB (43, 44). M<sub>3</sub>

receptors were previously regarded as the primary mediators of UBSM contraction and M<sub>2</sub> receptors were believed to play only a supportive role in bladder physiology via antagonizing smooth muscle relaxation induced by G<sub>i</sub>-coupled receptors (48). Nonetheless, the significant role of M<sub>2</sub> receptors in the contraction of detrusor muscle was clearly demonstrated by investigations in M<sub>2</sub> receptor-deficient mice (49). Interestingly, the expression of M<sub>2</sub> receptors is outnumbered by that of the M<sub>3</sub> receptors in most species, as the expression density of M<sub>2</sub> receptors is 3-fold higher (50); however, the reason for the abundance of M<sub>2</sub> receptors in the bladder remains to be clarified.

There is good evidence that the function and the expression level of the muscarinic receptors can change in the UB under pathophysiological conditions. The correlation between increased expression levels of M<sub>2</sub> and M<sub>3</sub> receptors in painful bladder syndrome and idiopathic detrusor overactivity suggested their significance in these disorders (40). Furthermore, the impairment of the detrusor function as a result of human prenatal mutation of the M<sub>3</sub> muscarinic receptor has also been reported (51). The expression level changes of the muscarinic receptors in OAB are rather conflicting as there are studies that reported the increased expression of M<sub>2</sub> and M<sub>3</sub> receptors in ovariectomy-induced bladder dysfunction as an animal model of post-menopausal overactive bladder (52); however, other groups demonstrated that there is no alteration of muscarinic receptors in association with OAB symptoms (53, 54). Mukerji *et al.* (2006) revealed the increase of M<sub>2</sub> and M<sub>3</sub> receptors by immunohistochemistry in bladder syndromes and their positive correlation with clinical scores (41). In addition, it has been reported that the M<sub>2</sub> receptors play a pivotal role in UB contraction in neurogenic bladder dysfunctions (55). The promising results of studies about the role of mAChRs under pathophysiological conditions initiated drug development for LUT disorders. Unfortunately; however, the development of small molecule antagonists with clear mAChR selectivity for treating UB disorders turned out to be extremely challenging because of the high degree sequence similarity of these receptors (56) explaining the wide range of adverse effects and low patient adherence associated with the usage of these medicines (57).

#### 1.4. G protein-coupled signaling pathways

The contraction of detrusor muscle cells can be triggered by the release of neurotransmitters from the nerve terminals. The main neurotransmitter to regulate contraction is ACh, which transmits its effects via muscarinic receptors. Muscarinic receptors belong to the family of G protein-coupled receptors (GPCRs) with seven-transmembrane domains with the role of the transmission of external stimuli into intracellular signaling cascades (56, 58). According to the literature, the signal through the GPCR is relayed directly by activating heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) or arrestin (59, 60). The signaling follows the classical paradigm of UBSM contraction with the activation of G proteins that are composed of  $\alpha$ ,  $\beta$  and  $\gamma$  subunits (61). The binding of the excitatory transmitter promotes the exchange of guanosine diphosphate (GDP) to guanosine-5'-triphosphate (GTP) on the GTPase binding domain of  $G\alpha$  resulting in the dissociation of  $G\alpha$  from  $G\beta\gamma$  subunits, each can mediate intracellular signaling on their own (61).

G proteins are classified into four families according to their  $G\alpha$  subunit:  $G_i$ ,  $G_s$ ,  $G_{12/13}$  and  $G_q$ . The  $G_q$  family consists of five members:  $G_q$ ,  $G_{11}$ ,  $G_{14}$ ,  $G_{15}$  and  $G_{16}$  (62, 63). The genes of the  $G_q$  and  $G_{11}$  proteins are linked explaining their almost identical functionality; however, their distribution is diverse in different tissues (62, 64). As mentioned previously, in the detrusor muscle,  $M_2$  and  $M_3$  receptors are considered to be the principal members of the muscarinic receptor family regulating smooth muscle contraction.  $M_2$  and  $M_3$  receptors are preferentially coupled to  $G_i$  and  $G_{q/11}$  proteins, respectively (29, 65). The  $G_q$ -mediated intracellular signaling involves the activation of the phospholipase C (PLC) enzyme, especially the  $PLC\beta$  isoform, by the  $G\alpha_q$  subunit (66). Although  $G_i$ -mediated signaling is typically considered to act via inhibition of the adenylyl cyclase activity, recently it has become clear that  $G_i$  is also capable of Rho activation in HEK 293 cells and bronchial smooth muscle (58, 67). In addition,  $PLC\beta$  can also be activated by  $G\beta\gamma$  dissociated from  $G_i$ -coupled GPCRs (68). Interestingly, according to Pfeil *et al.* (2020), the  $G_i$ -mediated  $Ca^{2+}$  signal cannot occur in the absence of  $G_q$  (69).

## 1.5. Intracellular signaling of smooth muscle contraction

The excitation and contraction process of the smooth muscle cells (SMCs) are mediated by two main mechanisms. The activation of the SMCs is regulated by  $\text{Ca}^{2+}$ -dependent and  $\text{Ca}^{2+}$ -independent,  $\text{Ca}^{2+}$  sensitizing signaling pathways. Recently, it has become clear that the  $\text{Ca}^{2+}$  sensitizing pathway also plays a pivotal role in the regulation of the excitation-contraction coupling and under physiological conditions these two mechanisms act simultaneously. The increase in intracellular  $\text{Ca}^{2+}$  levels can occur from the extracellular space or intracellular sources. To maintain the increased  $\text{Ca}^{2+}$  concentration in the intracellular space  $\text{Ca}^{2+}$  binds to the regulatory protein calmodulin (CaM) forming the  $\text{Ca}^{2+}$ –CaM complex (70-72). The consequent conformation change of CaM ensures the interaction with different molecular targets; for instance, myosin light-chain kinase (MLCK) (73). The activated MLCK increases myosin ATPase activity thereby phosphorylating the myosin light-chain (MLC) (74) leading to the interaction of actin and myosin chains, initiating the cross-bridge cycle and contraction (75). The decreasing concentration of intracellular  $\text{Ca}^{2+}$  leads to the dephosphorylation of MLC by myosin light-chain phosphatase (MLCP) resulting in smooth muscle relaxation. The inhibition of the MLCP strengthens smooth muscle contraction by increasing MLC phosphorylation resulting in hypercontractility (76).

### a) Calcium-dependent pathway of smooth muscle contraction

Among its peculiar coordination chemistry,  $\text{Ca}^{2+}$  plays an important role in the intracellular signaling of all cell types, including SMCs (71).  $\text{Ca}^{2+}$  can arise from the extracellular space through influx via various  $\text{Ca}^{2+}$  channels. Most importantly, voltage-gated  $\text{Ca}^{2+}$  channels open after the depolarization of the plasma membrane. In addition, the appearing  $\text{Ca}^{2+}$  triggers the activation of ryanodine (RyR) and inositol trisphosphate receptors ( $\text{IP}_3\text{R}$ ) in the sarcoplasmic reticulum (SR) consequently causing the efflux of  $\text{Ca}^{2+}$  from the SR into the cytoplasm (77, 78). However,  $\text{IP}_3\text{R}$  activation is predominantly induced by binding inositol 1,4,5-trisphosphate ( $\text{IP}_3$ ) which is a signaling molecule derived from the hydrolysis of phosphoinositol 4,5-bisphosphate by  $\text{PLC}\beta$  (66). Based on the literature, both the  $\text{Ca}^{2+}$  influx and the release of  $\text{Ca}^{2+}$  from SR are necessary for detrusor muscle contraction (79).

**b) Calcium sensitizing pathway of detrusor contraction**

$\text{Ca}^{2+}$  sensitization means the inhibition of the MLCP consequently inducing increased contraction force while  $\text{Ca}^{2+}$  is maintained at a constant level with MLCK activity (79, 80). Nevertheless, the modulation of  $\text{Ca}^{2+}$  sensitivity is not limited to the phosphorylation of myosin, but it can be achieved by changing the  $\text{Ca}^{2+}$  sensitivity of  $\text{IP}_3$ Rs or also by the phosphorylation of RyRs (81-83). Additionally,  $\text{Ca}^{2+}$  sensitivity does not seem to be affected by  $\text{IP}_3$  and it is also under examination whether diacylglycerol, the other product of PLC, has a considerable role in the regulation of  $\text{Ca}^{2+}$  sensitivity (84). Moreover, it was previously described, that both protein kinase C (PKC) and Rho proteins may induce increases in  $\text{Ca}^{2+}$  sensitivity (85, 86). However, other studies show that the sensitization mechanism is not augmented by PKC (87-89). In consideration of previous studies, the MLCK:MLCP ratio and the RhoA–Rho associated coiled-coil-containing protein kinase (ROCK) pathway are believed to be the dominant regulator of  $\text{Ca}^{2+}$  sensitivity (75, 84, 90-99).

The RhoA protein is a small, monomeric G protein belonging to the family of Ras, a protein family of small GTPases. Although Rho proteins have certain differences, similar to the above-mentioned heterotrimeric G proteins, they can also switch between their inactive and active states by binding GDP or GTP, respectively.

The regulation of Rho protein activation is implemented in three levels by guanine nucleotide dissociation inhibitor (GDI), GTPase-activating protein (GAP) and guanine nucleotide exchange factor (GEF). Furthermore, it has been noted that high protein kinase G expression level is associated with the regulation of Rho transcription, suggesting that the overall activity of Rho proteins can also be regulated transcriptionally (100). By default, GDI binds by its lipid tails to the Rho protein forming a soluble complex in the cytosol. Because of the high affinity of GDP and the very slow hydrolysis of GTP, the switch between the active and inactive phase of Rho proteins needs the support of GEFs and GAPs to accelerate GDP dissociation and the GTP hydrolysis, respectively (101). Posttranslational modification on the C terminal may lead to the activation of Rho by the dissociation of GDI by the GDI displacement factor, which is the first step of the activation process. It is necessary to provide an appropriate phospholipid microenvironment for the function of Rho GTPases in order to alter signal molecules' activities and roles (e.g.: p115-RhoGEF needs to bind with the

activated  $G\alpha_{12/13}$  protein leading to RhoA activation) (102). Modification of the nucleotide binding site of Rho by GEF eventuates the release of Rho proteins from GDI-bound complexes resulting in an increased amount of GTP-bound Rho proteins by the discharge of GDP (101).

Although more than 30 effector proteins have been identified that interact with the activated Rho, the first established and most studied effector proteins are the ROCKs with diverse biological effects (103-106). Interestingly, ROCKs are key regulators of the  $Ca^{2+}$  sensitization mechanism in the smooth muscle. The two protein isoforms encoded by the ROCK genes (*Rock1* and *Rock2*) share 62 % sequence identity and their distribution throughout the body differs markedly. The mRNA of the ROCK<sub>2</sub> enzyme is principally expressed in the brain and heart, whereas the ROCK<sub>1</sub> is mostly presented in other tissues. Both the ROCK<sub>1</sub> and ROCK<sub>2</sub> enzymes are found in the UB at both mRNA and protein levels (107-109). ROCK enzymes are members of the AGC kinase family (110) with three major domains: a Rho binding domain (RBD), a kinase domain and a cysteine-rich domain (103, 111). With regard to the observation that their kinase domains are 83 % identical, it has been suggested that they may exhibit similar substrate specificity (112). Both ROCK isoforms are activated by the binding of the Rho protein to the RBD region (104, 106) resulting in the loss of the negative regulatory role of RBD and activation of ROCK (112). Subsequently, ROCK will be able to phosphorylate its target proteins such as MLCP at the myosin phosphatase-targeting subunit 1 causing a reduction of MLCP activity and consequently an increase of phosphorylated MLC (113). Furthermore, it has been suggested that the ROCK can directly phosphorylate MLC *in vitro* (114, 115) and GAP proteins can also be phosphorylated by ROCK resulting in a prolonged Rho activation suggesting the formation of a positive feedback loop in the regulation of the Rho–ROCK pathway (116). Taken together, the activation of the Rho–ROCK pathway goes hand in hand with decreased MLCP activity and increased phosphorylation of MLC; therefore, the activation of smooth muscle contraction.

It has been reported that the inhibition of  $Ca^{2+}$  sensitization by bacterial toxins shows agonist, tissue and species specificity indicating that other pathways may also lead to  $Ca^{2+}$  sensitization (91, 97, 117, 118). Further investigations of these pathways would accelerate the understanding of smooth muscle contraction at the molecular level

and may provide pharmacological targets in diseases related to smooth muscle hyper-reactivity.

### **1.6. ROCK as a pharmacological treatment target for the disorders of the urinary bladder**

It has been reported that the Rho–ROCK pathway is involved in a variety of diseases in different species and tissues. The involvement of the ROCK has been established in the regulation of neuronal cell function as well (119). Furthermore, ROCK inhibitors showed potential therapeutic effects in Alzheimer's disease, Parkinson's disease and epilepsy (120-124). In addition, it has also been demonstrated to play an important role in smooth muscle-related diseases/disorders. Inhibition of Rho–ROCK is proposed to be a promising therapeutic target in the treatment of hypertension as well as coronary and cerebral artery vasospasm via the inhibition of smooth muscle contraction (125, 126). Moreover, Mayra *et al.* (2020) indicated that ROCK has a pivotal role in airway smooth muscle hyper-contractility (76). Furthermore, diabetes-associated upregulation of Rho–ROCK and increased contractility of gastric smooth muscle were demonstrated in a study by Mahavadi *et al.* (2017) (127).

Moreover, increased  $Ca^{2+}$  sensitivity of the regulatory and contractile proteins appears to maintain spontaneous detrusor muscle contractile activity in pathophysiological conditions (75). The elevation of the Rho and ROCK expression levels was found in UB hypertrophy allowing detrusor contractions at low  $Ca^{2+}$  concentration, thereby explaining the sustained contraction response under this condition (128, 129). Furthermore, the role of the ROCK in diabetes-associated bladder dysfunction was suggested previously (108, 130). In addition, an increased expression of RhoA protein has been reported in urinary bladder tissues isolated from spontaneous hypertensive rats with OAB symptoms; however, the expression level of ROCK has not been elucidated (131). Braverman *et al.* (2006) suggested an enhanced role of ROCK in mediating UB contraction in denervated bladder compared to normal bladders (132). In addition, ROCK inhibition had a significant reducing effect on muscarinic receptor-mediated bladder contractions in a rat model of cyclophosphamide-induced cystitis (133, 134). Moreover, the importance of the Rho–ROCK pathway in the

pathophysiology of bladder dysfunctions is also emphasized by the fact that a ROCK inhibitor, fasudil, can alleviate detrusor overactivity in a rat OAB model (135). Interestingly, it has also been reported that ROCK activity increases with age, as does the occurrence of voiding disorders (135-137). Furthermore, the impairment of estrogen deficiency on the expression and function of ROCK has been demonstrated after ovariectomy which might explain the greater incidence of OAB after menopause in women (138-140).

## 2. Objectives

Although ACh plays an essential role in the regulation of micturition and the alterations of cholinergic neurotransmission have been implicated in the pathogenesis of urinary bladder dysfunctions, our knowledge of the signaling pathways involved in ACh-induced detrusor contraction still remains incomplete.

Antimuscarinics are widely used in the management of OAB, yet several adverse effects limit their application and patients' compliance. Moreover, it has been demonstrated that the Rho–ROCK pathway plays a pivotal role in the regulation of detrusor contraction. Thus, we aimed to better understand the signal transduction of mAChRs and the role of the RhoA–ROCK pathway in murine and human UBSM. Our final goal is to provide a theoretical basis for the development of a more specific medication for OAB with fewer adverse effects.

Specifically, our main objectives were

- to determine which mAChRs mediate carbamoylcholine (CCh)-induced UBSM contractions,
- to identify the G proteins involved in signaling and
- to reveal the intracellular signaling pathways of mAChRs in UBSM, focusing on the role of the RhoA–ROCK pathway.

### 3. Methods

#### 3.1. Animals

All procedures were carried out according to the guidelines of the Hungarian Law of Animal Protection (28/1998) and were approved by the Government Office of Pest County (Permission numbers: PEI/001/2709-13/2014, PE/EA/925-7/2021).

UBs were obtained from adult male (90–120 days old, 30–35 g), C57BL/6N wild type (WT) mice (from Charles River Laboratories, Isaszeg, Hungary) and from animals deficient in the mAChRs [M<sub>2</sub>-KO, M<sub>3</sub>-KO, M<sub>2</sub>/M<sub>3</sub>-KO] (141) developed in the Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, USA. In an additional group of mice, G $\alpha_{q/11}$  signaling was conditionally inactivated in a smooth muscle-specific manner (G $\alpha_{q/11}$ -KO). The mouse line with smooth muscle-specific inducible deletion of the G $\alpha_{q/11}$  signaling pathway was generated on a G $\alpha_{i1}$ -deficient (*Gna11*<sup>-/-</sup>) background (142) with floxed alleles of the genes coding G $\alpha_q$  (*Gnaq*<sup>flox/flox</sup>) and expressing a fusion protein of Cre recombinase mutated human estrogen receptor ligand binding domain (Cre-ERT2) (143) under the control of the smooth muscle myosin heavy chain (SMMHC) promoter. Deletion of *Gnaq* was induced by intraperitoneal tamoxifen injection (1 mg/day for 5 consecutive days) in SMMHC-CreERT2<sup>+/-</sup>;*Gnaq*<sup>flox/flox</sup>;*Gna11*<sup>-/-</sup> mice as described (144). Tamoxifen-treated SMMHC-CreERT2<sup>-/-</sup>;*Gnaq*<sup>flox/flox</sup>;*Gna11*<sup>+/+</sup> animals served as controls and are referred to as G $\alpha_{q/11}$ -CTRL.

Inactivation of G $\alpha_i$  proteins was achieved by intraperitoneal administration of pertussis toxin (PTX) (145) every 24 hours for six times. The control (CTRL) animals received vehicle treatment in the same way as PTX-treated ones. The effectiveness of the PTX treatment was monitored in Langendorff-perfused heart preparations with the methodology described previously (146). Briefly, the lack of the G $\alpha_i$ -mediated heart-rate-reducing effect of ACh verified the inactivation of G $\alpha_i$  proteins.

#### 3.2. Human urinary bladder tissues

All procedures involving human UB tissues have been approved by the Scientific and Research Committee of the Medical Research Council of Hungary (License No.: 21545-2/2019/EKU). Human UB tissues were obtained from 19 patients (15 males, 4

females; mean age of  $65.5 \pm 9.3$  years, range between 44 and 78 years) undergoing open radical cystectomy due to muscle-invasive bladder malignancy after having obtained written patient consent. None of the patients had any urodynamic disorders, symptoms of OAB syndrome, or were taking drugs for OAB.

Following the surgical removal of the bladders, they were immediately placed in physiological saline solution and transported to the Department of Pathology, Forensic and Insurance Medicine of Semmelweis University, Budapest. Here, an approximately  $3 \times 2$  cm piece of healthy, tumor-free whole bladder wall tissue was excised by a uro-pathologist within approximately 15–20 min following removal of the bladders from patients. The healthy bladder tissue was immediately placed into room temperature Hank's Balanced Salt Solution and transported to the myograph laboratory, where preparation of the smooth muscle strips was performed immediately. Overall, myographic experiments started within 45–60 min following bladder removal from the patients.

### **3.3. Preparation of smooth muscle strips**


After the euthanasia of the mice by carbon dioxide (CO<sub>2</sub>) asphyxiation, the UBs were removed and placed into Krebs solution (119 mM NaCl, 4.7 mM KCl, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 2.5 mM CaCl<sub>2</sub>·H<sub>2</sub>O, 1.2 mM MgSO<sub>4</sub>·7H<sub>2</sub>O, 20 mM NaHCO<sub>3</sub>, 0.03 mM EDTA and 10 mM glucose, pH 7.4) at room temperature. Under a dissection microscope (M3Z; Wild Heerbrugg AG, Gais, Switzerland) the serosal surface was cleaned from adipose and connective tissues. Bladders were cut longitudinally into two or four equal-length strips for RhoA activity assay and measurement of bladder contractility, respectively. The whole mucosal layer (urothelium + submucosa) was also gently removed to prevent the potential release of paracrine factors from the urothelium or submucosal tissue and to avoid tension changes related to the contraction of myofibroblasts (147, 148).

Human UB specimens were also placed into Krebs solution at room temperature during the preparation. Under a dissection microscope, the serosal tissue and the mucosal layer were removed. The isolated detrusor muscle specimens were cut into equal, approximately  $3 \times 2 \times 1$  mm strips for myography.

### 3.4. Myography, determination of concentration-response curves


Detrusor muscle strips were mounted perpendicularly on two parallel tissue-holding needles of a myograph (200- $\mu$ m needles, 610 M Multi Wire Myograph System, Danish Myo Technology A/S, Aarhus, Denmark). Chambers were filled with 6 mL of 37 °C Krebs solution aerated with carbogen (mixture of 5 % CO<sub>2</sub> and 95 % O<sub>2</sub>). Detrusor muscle contractions were registered under isometric conditions. The emerging contraction force was measured along the longitudinal axis of the samples parallel with the axis of the force transducer.

Every experiment started with a 60-minute resting period while the UB strips were stretched to and stabilized at a resting tension of 5 mN. After the equilibration period, the UBSM was challenged twice with 124 mM K<sup>+</sup>-containing Krebs solution (made by iso-osmolar replacement of Na<sup>+</sup> by K<sup>+</sup>) to test the viability of the tissues. To investigate the contractility of UBSM strips from mice of different experimental groups, we compared their responses to the 124 mM KCl solution. The contractile forces did not show statistically significant differences in different mouse strains, implying that they show a similar ability to generate UBSM contraction. However, according to the recommendation of Erdogan *et al.* 2020 (149) in the case of using K<sup>+</sup>-induced contraction as a reference, we are presenting quantitative KCl responses for each experimental group in Figures 1 and 2.



**Figure 1 | Comparison of urinary bladder smooth muscle (UBSM) contractions induced by 124 mM KCl solution in wild type (WT) and muscarinic receptor M<sub>2</sub>-, M<sub>3</sub>-, M<sub>2</sub>/M<sub>3</sub>-knockout (KO) mice<sup>1</sup>.** Contractions induced by 124 mM KCl solution did not differ significantly in UBSM strips prepared from WT or KO animals. WT:  $n = 6$ , M<sub>2</sub>-KO:  $n = 16$ , M<sub>3</sub>-KO:  $n = 15$ , M<sub>2</sub>/M<sub>3</sub>-KO:  $n = 8$ . Kruskal-Wallis test,  $P < 0.05$  was considered as significant difference.

<sup>1</sup> Balla, Helga; Borsodi, Kinga; Örsy, Petra; Horváth, Béla; Molnar, Peter J.; Lénárt, Ádám; et al. (2023). Supplemental Material Intracellular signaling pathways of muscarinic acetylcholine receptor-mediated detrusor muscle contractions. figshare. Figure. <https://doi.org/10.6084/m9.figshare.23859108.v1> (150)



**Figure 2 | Comparison of detrusor contractions induced by 124 mM KCl solution in  $G\alpha_{q/11}$  control (CTRL) and knockout (KO) mice<sup>2</sup>.** Contractions induced by 124 mM KCl solution did not differ significantly in detrusor strips prepared from CTRL or KO animals.  $G\alpha_{q/11}$ -CTRL:  $n = 9$ ,  $G\alpha_{q/11}$ -KO:  $n = 9$ . Mann-Whitney test,  $P < 0.05$  was considered as significant difference.

After determining the  $K^+$ -induced responses, the chambers were washed several times with normal Krebs solution and a 25-30 min resting period was allowed before obtaining cumulative concentration-response curves of CCh ( $10^{-4}$ - $10^{-8}$  M). Some of the strips were incubated with the ROCK inhibitor Y-27632 (1  $\mu$ M or 10  $\mu$ M, 20 min) before the administration of the agonist. The concentration of Y-27632 that was used in the present study reportedly inhibits both ROCK<sub>1</sub> and ROCK<sub>2</sub> without any effects on other kinases in the detrusor muscle (107). Finally, bladder strips were exposed to 124 mM  $K^+$ -containing Krebs solution to retest the viability of the detrusor strips at the end of the experiment. CCh-induced contractions were expressed as the percentage of the contraction induced by 124 mM  $K^+$  (second administration) in the same preparation.

<sup>2</sup> Balla, Helga; Borsodi, Kinga; Örsy, Petra; Horváth, Béla; Molnar, Peter J.; Lénárt, Ádám; et al. (2023). Supplemental Material Intracellular signaling pathways of muscarinic acetylcholine receptor-mediated detrusor muscle contractions. figshare. Figure. <https://doi.org/10.6084/m9.figshare.23859108.v1> (150)

For the acquisition and analysis of myographic measurements, the MP100 system and AcqKnowledge 3.9.1 software from Biopac Systems (Goleta, CA) were used. The moving average smoothing function of the software was applied on recordings solely to eliminate the noises arising from the bubbling of the medium and to reduce the high-frequency, low-amplitude spontaneous tension oscillations. The parameters of the smoothing filter were carefully chosen in order to eliminate only the noises but not to alter the amplitude of the CCh-induced responses; therefore, the baseline and peak values of contractions were always compared before and after the smoothing. The sample rate of the recordings was 10 samples/s (10 Hz) and the smoothing factor was between 10 and 40 samples.

### **3.5. Quantification of RhoA activation**

Mouse UBs were cut into half and the detrusor muscle was prepared as described above. After 60 min of resting, bladder strips were pre-stretched to 5 mN in myograph chambers containing normal Krebs solution. Next, one-half of each bladder was challenged with a single dose of CCh ( $3 \times 10^{-5}$  M, which induces submaximal contraction) or its vehicle. At 3 min after the CCh or vehicle administration, the strips were removed and rapidly snap frozen in liquid nitrogen to stop enzyme activity immediately.

To quantify the amount of activated and total RhoA protein, a RhoA G-LISA Activation Assay Kit and Total RhoA ELISA Assay Kit were used, respectively. In addition to the recommended assay protocols, the lysis buffer was supplemented with protease and phosphatase inhibitors (1 % Cytoskeleton protease inhibitor cocktail, 50 mM sodium fluoride, 1 % phosphatase inhibitor cocktail and 1 mM 4-nitrophenyl phosphate). Activated RhoA-GTP was normalized to the total RhoA content. Vehicle-treated baseline and its paired CCh-activated RhoA activity measurements were performed from the two halves of the same UB.

### **3.6. Evaluation of gene expression**

UBSM strips of WT,  $M_2^-$ ,  $M_3^-$ ,  $M_2/M_3$ -KO mice were stored at  $-80$  °C until quantitative polymerase chain reaction (qPCR) analysis. Detrusor samples were homogenized (BEL-19923-0000, Capitol Scientific, Austin, TX, USA) and subsequently lysed in 0.5 ml Tri Reagent. A total of 0.2 ml chloroform was added per

1 ml Tri Reagent and the samples were mixed for 15 seconds by vigorous shaking. Phase separation was allowed by placing the samples at room temperature for 15 min followed by centrifugation at  $12,000 \times g$  for 15 min at  $4^\circ\text{C}$ . The upper aqueous phase was transferred to a fresh tube. 0.5 ml isopropanol/1 ml Tri Reagent was added, thoroughly mixed, incubated for 10 min and centrifuged at  $12,000 \times g$  for 10 min at  $4^\circ\text{C}$  to precipitate the ribonucleic acid (RNA). The RNA pellet was washed with 2 ml ethanol per 1 ml Tri reagent and centrifugated at  $12,000 \times g$  for 8 min at  $4^\circ\text{C}$ . The supernatant was aspirated and the sediment was air-dried. Total RNA was dissolved in UltraPure water and RNA quantity and purity of all samples were measured with a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, USA). Total RNA samples were stored at  $-80^\circ\text{C}$  until use.

First-strand complementary deoxyribonucleic acid (cDNA) was prepared from tissue RNA preparations using RevertAid First Strand cDNA Synthesis kit and Bio-Rad C1000 Touch PCR thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA). Reverse transcription was carried out according to the manufacturer's instructions using the following temperature cycles:  $25^\circ\text{C}$  for 5 min,  $42^\circ\text{C}$  for 60 min and  $70^\circ\text{C}$  for 5 min. Thereafter, the cDNA was stored at  $-20^\circ\text{C}$  until further analysis.

Specific primer sets were designed by using Primer3Plus (<https://www.primer3plus.com/>) and/or Primer-BLAST software (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>) and obtained from Sigma-Aldrich (151, 152). The PCR primer sequences are listed in Table 1.

qPCR reactions were performed on CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) using SsoAdvanced Universal SYBR Green Supermix. The sample volume was 10  $\mu\text{l}$  containing 2  $\mu\text{l}$  diluted cDNA, 1  $\mu\text{l}$  forward and 1  $\mu\text{l}$  reverse primer (0.5-0.5  $\mu\text{M}$ ), 5  $\mu\text{l}$  SsoAdvanced Universal SYBR Green Supermix and UltraPure water. All experiments were performed in triplicate. Temperature cycles were as follows:  $95^\circ\text{C}$  for 60 s,  $95^\circ\text{C}$  for 10 s and  $58^\circ\text{C}$  for 30 s (40 cycles), followed by a melting curve analysis by heating from  $65^\circ\text{C}$  to  $95^\circ\text{C}$  with a rate of  $0.5^\circ\text{C}/\text{s}$  and continuous fluorescence measurement. The specific PCR products were analyzed by gel electrophoresis to exclude the presence of primer dimers and verify the correct PCR product length.

**Table 1** | The gene identities and forward (F) and reverse (R) primer sequences used for transcriptomic analysis of different genes.

Gene name	Primer sequence	NCBI reference sequence number	Reference
<b>Target genes</b>			
<i>Chrm1</i> (cholinergic receptor, muscarinic 1)	F: AAGTGGCATTTCATCGGGATCACCAC R: TGTTGACCTTGAAGGAGATGAGCAC	NM_007698.3	(153)
<i>Chrm2</i> (cholinergic receptor, muscarinic 2)	F: GCTATTACCAGTCCTTACAAGACA R: CCAGAGGATGAAGGAAAGAACC	NM_203491.4	(154)
<i>Chrm3</i> (cholinergic receptor, muscarinic 3)	F: AGGGCTGACTACTTAATCTTGGATA R: TGCAAGGTCATTGTGACTCTC	NM_033269.4	(155)
<i>Chrm4</i> (cholinergic receptor, muscarinic 4)	F: TGAAGGTCTCCAGAGGTGGG R: TTTAGAGACCTGGGGTCCTTC	NM_007699.3	(152)
<i>Chrm5</i> (cholinergic receptor, muscarinic 5)	F: TACTATTGCAGCTGTGACCG R: GCCAAGCTGAGCAGGTAATA	NM_205783.2	(152)
<i>Rock1</i> (Rho-associated coiled-coil containing protein kinase 1)	F: ACCAGGGCATCCAATCCATC R: GCATCATGTCGACTGGGGAC	NM_009071.2	(152)
<i>Rock2</i> (Rho-associated coiled-coil containing protein kinase 2)	F: GGCGAGAATGTGATTGGTGG R: GTTCTACAAGTGAATCTGCGT	NM_009072.2	(152)
<b>Reference gene</b>			
<i>B2m</i> (beta-2 microglobulin)	F: CTTTCTGGTGCTTGTCTCACTG R: AGTATGTTTCGGCTTCCCATTC	NM_009735.3	(152)

### 3.7. Drugs and solutions

Carbamoylcholine was purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in saline to a stock solution of  $2 \times 10^{-1}$  M. Y-27632 was from Cayman Chemical (Ann Arbor, MI, USA) and it was dissolved in saline to  $10^{-3}$  M stock solution. RhoA G-LISA Activation Assay Kit (Colorimetric format, catalog no. BK124), Total RhoA ELISA Assay (catalog no. BK150) and Cytoskeleton protease inhibitor cocktail (catalog no. PIC02) were purchased from Cytoskeleton (Denver, CO, USA). PTX was purchased from Cayman Chemical (Ann Arbor, MI, USA) and was dissolved in 20:80 glycerin:phosphate buffered saline (PBS) to 50  $\mu$ g/500 ml stock solution. Before the administration, the stock solution was diluted 20-fold with saline. Isopropanol (catalog no. 59304), the RevertAid First Strand cDNA Synthesis kit (catalog no. K1621) and UltraPure water (Invitrogen) were from Thermo Scientific (Waltham, MA, USA). Tri Reagent (catalog no. R2050-1-50) was purchased from Zymo Research (Irvine, CA, USA) and chloroform was from Reanal Laborvegyszer Kft

(Budapest, Hungary). Ethanol and SsoAdvanced Universal SYBR Green Supermix were purchased from Molar Chemicals Kft (Budapest, Hungary) and Bio-Rad Laboratories (Hercules, CA, USA), respectively. All other reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).

### 3.8. Data analysis and statistics

The CCh-induced detrusor muscle contraction was defined as the peak value of tension developed after the addition of each concentration of CCh.

Raw qPCR data were analyzed using CFX Maestro Software 2.2 software (Bio-Rad Laboratories, Hercules, CA, USA). Data evaluation, statistical analysis and graphs were performed by GraphPad Prism software (v.6.07; GraphPad Software Inc., La Jolla, CA, USA).

The Pfaffl algorithm, also known as the delta–delta CT ( $\Delta\Delta CT$ ) method, with efficiency correction, was used to calculate the expression of the  $\beta$ -2 microglobulin (*B2m*), M<sub>1</sub> receptor gene (*Chrm1*), M<sub>2</sub> receptor gene (*Chrm2*), M<sub>3</sub> receptor gene (*Chrm3*), M<sub>4</sub> receptor gene (*Chrm4*), M<sub>5</sub> receptor gene (*Chrm5*) along with *Rock1* and *Rock2* genes (156, 157). *B2m* was considered as the housekeeping gene for normalizing gene expression. For *B2m*, efficiency was 1.13; for M<sub>1</sub>: 1.1; for M<sub>2</sub>: 0.9; for M<sub>3</sub>: 1.05; for M<sub>4</sub>: 1.06; for M<sub>5</sub>: 0.97; for ROCK<sub>1</sub>: 1.08; and for ROCK<sub>2</sub>: 0.99. The minimum information for the publication of quantitative real-time PCR experiments (MIQE) guidelines was followed during the entire qPCR quantification workflow (157).

All experimental data are presented as means  $\pm$  SEM and *n* represents the number of cases.


For statistical analysis, the Mann-Whitney test or Kruskal-Wallis test was used and  $P < 0.05$  was considered a statistically significant difference. Statistical analysis and graph plotting were performed with GraphPad Prism software (v.6.07; GraphPad Software Inc., La Jolla, CA, USA).

Concentration-response curves were analyzed with nonlinear regression and the calculated E<sub>max</sub> and EC<sub>50</sub> values are presented on the figures as table inserts.

## 4. Results

### 4.1. The Rho–ROCK pathway has a major role in the regulation of carbamoylcholine (CCh)-induced smooth muscle contraction in murine and human urinary bladder


We first examined the role of the RhoA–ROCK pathway in CCh-induced contractile responses in murine UBSM strips (Figure 3). The concentration-dependent contractions were significantly reduced by the ROCK inhibitor Y-27632 (1  $\mu$ M or 10  $\mu$ M, 20 min incubation). At a concentration of 1  $\mu$ M, Y-27632 reduced the  $E_{max}$  from 75.8 % to 63.9 %, whereas the  $EC_{50}$  values were not significantly different as compared to control ( $5.2 \times 10^{-7}$  M vs.  $4.3 \times 10^{-7}$  M, respectively). In contrast, when the strips were incubated with 10  $\mu$ M Y-27632, both the  $E_{max}$  and the  $EC_{50}$  values differed statistically from those of controls ( $E_{max} = 49.6$  %,  $EC_{50} = 9.0 \times 10^{-7}$  M). These results suggested that the ROCK enzyme plays a substantial role in mediating CCh-induced contractions in murine UBSM strips.



**Figure 3 | Role of Rho kinase (ROCK) in mediating carbamoylcholine (CCh)-induced contraction in murine urinary bladder smooth muscle (150).** In mouse detrusor muscle, contractile responses induced by CCh were reduced in the presence of

the ROCK inhibitor (Y-27632, 1 and 10  $\mu\text{M}$ ). At 1  $\mu\text{M}$ , Y-27632 reduced the  $E_{\text{max}}$  of the concentration-response curve, whereas there was no statistical difference between the  $EC_{50}$  values. However, when Y-27632 was applied at 10  $\mu\text{M}$ , both the  $EC_{50}$  and the  $E_{\text{max}}$  values were statistically different from control (CTRL). CTRL:  $n = 14$ , 1  $\mu\text{M}$  Y-27632:  $n = 12$ , 10  $\mu\text{M}$  Y-27632:  $n = 8$ . \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .

Thereafter, we investigated the influence of the ROCK inhibitor Y-27632 (10  $\mu\text{M}$ , 20 min incubation) on CCh-induced ( $10^{-6}$  M) detrusor contractions in the human UB (Figure 4). Similar to our murine results, the ROCK inhibitor decreased CCh-induced contractile responses of the human detrusor muscle as well. These results indicate that the RhoA–ROCK pathway plays an indispensable role in contractions induced by CCh both in murine and human UB.



**Figure 4 | The Rho kinase (ROCK) enzyme has a major role in carbamoylcholine (CCh)-induced detrusor contraction in the human urinary bladder<sup>3</sup>.** Pretreatment of human urinary bladder smooth muscle strips with the ROCK inhibitor Y-27632

<sup>3</sup> Borsodi, Kinga; Balla, Helga; Molnar, Peter J.; Lénárt, Ádám; Kenessey, István; Horváth, András; et al. (2021). Supplementary figure 5B. The effect of Y-27632 pretreatment on 124 mM KCl-, CCh- and  $\alpha,\beta$ -meATP-induced contractions and on bladder tone in human detrusor muscle. figshare. Figure. <https://doi.org/10.6084/m9.figshare.16815088.v5> (158)


(10  $\mu$ M, 20 min) reduced contractions induced by CCh ( $10^{-6}$  M). CTRL:  $n = 10$ , Y-27632:  $n = 15$ . Mann-Whitney test, \*\*\* $P < 0.001$ .

## 4.2. The role of the M<sub>2</sub> and M<sub>3</sub> receptors in the detrusor muscle contraction and RhoA activation induced by carbamoylcholine (CCh)

Our next aim was to identify the muscarinic receptor(s) mediating the activation of the RhoA–ROCK pathway and contraction in UBSM upon cholinergic stimulation. As UBSM principally expresses M<sub>2</sub> and M<sub>3</sub> muscarinic receptors (44, 159), we investigated CCh-induced contractions in UBSM preparations from M<sub>2</sub>-KO, M<sub>3</sub>-KO and M<sub>2</sub>/M<sub>3</sub>-KO double-knockout mice (Figure 5). The concentration-response curve of CCh was markedly changed in detrusor strips lacking either M<sub>2</sub> (EC<sub>50</sub> =  $2.2 \times 10^{-6}$  M, E<sub>max</sub> = 97.5 %) or M<sub>3</sub> receptors (EC<sub>50</sub> =  $1.4 \times 10^{-6}$  M, E<sub>max</sub> = 42.2 %), as compared to CTRL (EC<sub>50</sub> =  $5.0 \times 10^{-7}$  M, E<sub>max</sub> = 103.3 %) (Figure 5A). Moreover, the contractile responses were completely abolished in M<sub>2</sub>/M<sub>3</sub>-KO UBSM strips (Figure 5A), demonstrating that both M<sub>2</sub> and M<sub>3</sub> receptors, but no other muscarinic receptors contribute to CCh-induced UBSM contractions.

Since the main goal of this study was to investigate the RhoA–ROCK pathway, we also tested the effect of CCh ( $3 \times 10^{-5}$  M, 3 min) on RhoA activation in WT and muscarinic receptor-deficient animals. CCh-induced RhoA activation was significantly decreased in M<sub>2</sub>-KO and M<sub>3</sub>-KO bladder strips, compared to that of WT preparations. Moreover, CCh-induced RhoA activation was completely abolished in M<sub>2</sub>/M<sub>3</sub>-KO UBSM (Figure 5B), indicating that both M<sub>2</sub> and M<sub>3</sub>, but no other receptors, are involved in RhoA activation. Furthermore, Y-27632 (10 μM, 20 min) was able to induce an additional inhibition of CCh-induced contractions in both M<sub>2</sub>-KO (Figure 5E) and M<sub>3</sub>-KO (Figure 5F) bladders, indicating that neither M<sub>2</sub> nor M<sub>3</sub> receptors play an exclusive role in activating the RhoA–ROCK pathway.


Based on data gained by other research groups it seems to be implausible that the lack of one specific muscarinic receptor gene would alter the expression level of the other four muscarinic receptor subtypes (160-164). Therefore, we investigated the expression levels of the different muscarinic receptors in the UBSM from muscarinic receptor KO mice to confirm if there are any effects of the single gene deletion on other receptor subtypes. Our results show that there is no impact of the M<sub>2</sub> and M<sub>3</sub> gene deletion on mRNA expression levels of the other receptors in UBSM strips from M<sub>2</sub>- and M<sub>3</sub>-KO mice (Figure 5C, D). In addition, the qPCR analysis confirmed the lack of *Chrm2* and *Chrm3* in the M<sub>2</sub>- and M<sub>3</sub>-KO mice, respectively and in double KO animals.



**Figure 5 | Carbamoylcholine (CCh)-induced detrusor contraction and RhoA activation are mediated by both M<sub>2</sub> and M<sub>3</sub> muscarinic acetylcholine receptors (150).** A: CCh-induced contractions were markedly impaired in detrusor strips lacking

either M<sub>2</sub> (M<sub>2</sub>-KO) or M<sub>3</sub> receptors (M<sub>3</sub>-KO). Furthermore, the contractile response to CCh was completely abolished in urinary bladder smooth muscle (UBSM) strips deficient in both M<sub>2</sub> and M<sub>3</sub> receptors (M<sub>2</sub>/M<sub>3</sub>-KO). B: CCh ( $3 \times 10^{-5}$  M)-induced RhoA activation significantly decreased in both M<sub>2</sub>-KO and M<sub>3</sub>-KO mouse bladders and abolished in M<sub>2</sub>/M<sub>3</sub>-KO UBSM. C: No statistical difference was observed in M<sub>2</sub> receptor gene (*Chrm2*) expression in the M<sub>3</sub> receptor-deficient animals compared to wild type (WT). D: The expression of the M<sub>3</sub> receptor gene (*Chrm3*) was unaffected by the lack of M<sub>2</sub> receptors. E: ROCK inhibitor (Y-27632, 10  $\mu$ M), induced a further marked decrease in contraction in M<sub>2</sub>-KO mouse bladder strips. F: CCh-induced contractions were abolished completely by Y-27632 (10  $\mu$ M) in UBSM strips deficient in M<sub>3</sub> receptors. A: WT:  $n = 6$ , M<sub>2</sub>-KO:  $n = 16$ , M<sub>3</sub>-KO:  $n = 15$ , M<sub>2</sub>/M<sub>3</sub>-KO:  $n = 8$ , B: WT:  $n = 9$ , M<sub>2</sub>-KO  $n = 8$ , M<sub>3</sub>-KO  $n = 8$ , M<sub>2</sub>/M<sub>3</sub>-KO = 9, C: WT:  $n = 5$ , M<sub>2</sub>-KO:  $n = 5$ , M<sub>3</sub>-KO:  $n = 5$ , M<sub>2</sub>/M<sub>3</sub>-KO:  $n = 5$ , D: WT:  $n = 8$ , M<sub>2</sub>-KO:  $n = 6$ , M<sub>3</sub>-KO:  $n = 5$ , M<sub>2</sub>/M<sub>3</sub>-KO:  $n = 10$ , E: M<sub>2</sub>-KO  $n = 16$ , Y-27632:  $n = 8$ , F: M<sub>3</sub>-KO:  $n = 6$ , Y-27632:  $n = 8$ . B, C, D: Kruskal-Wallis test, NS not significant, \* $P < 0.05$ , \*\*\* $P < 0.001$ .

Furthermore, there is no change in the expression levels of the other three muscarinic receptor subtypes ( $M_1$ ,  $M_4$ ,  $M_5$ ) in detrusor strips deficient in  $M_2$ ,  $M_3$  or  $M_2/M_3$  muscarinic receptors (Figure 6).




**Figure 6 | Expression levels of  $M_1$ ,  $M_4$  and  $M_5$  receptor genes (*Chrm1*, *Chrm4*, *Chrm5*) in detrusor strips from  $M_2$ -,  $M_3$ -,  $M_2/M_3$ -knockout (KO) mice<sup>4</sup>.** A: The expression of *Chrm1* was unaffected by the lack of  $M_2$  and  $M_3$  receptors. B: No statistical difference was observed in  $M_4$  receptor gene expression in the receptor-deficient animals compared to wild type (WT). C: The amount of the *Chrm5* did not change in  $M_2$ -,  $M_3$ - and  $M_2/M_3$ -KO mice compared to that of controls. A: WT:  $n = 6$ ,  $M_2$ -KO:  $n = 5$ ,  $M_3$ -KO:  $n = 5$ ,  $M_2/M_3$ -KO:  $n = 9$ , B: WT:  $n = 5$ ,  $M_2$ -KO:  $n = 5$ ,  $M_3$ -KO:

<sup>4</sup> Balla, Helga; Borsodi, Kinga; Örsy, Petra; Horváth, Béla; Molnar, Peter J.; Lénárt, Ádám; et al. (2023). Supplemental Material Intracellular signaling pathways of muscarinic acetylcholine receptor-mediated detrusor muscle contractions. figshare. Figure. <https://doi.org/10.6084/m9.figshare.23859108.v1> (150)

$n = 5$ ,  $M_2/M_3$ -KO:  $n = 10$ , C: WT:  $n = 6$ ,  $M_2$ -KO:  $n = 5$ ,  $M_3$ -KO:  $n = 6$ ,  $M_2/M_3$ -KO:  $n = 8$ . Kruskal-Wallis test,  $P < 0.05$  was considered as significant difference.

Interestingly, neither the deletion of  $M_2$  nor that of  $M_3$  induced any significant change in the mRNA expression of  $ROCK_1$  or  $ROCK_2$ , whereas  $M_2/M_3$  double KOs showed increased  $ROCK_2$  expression, probably as a counter-regulation of diminished muscarinic receptor signaling in the UBSM (Figure 7). It is noteworthy that in contrast to  $M_2$ -KO preparations, the ROCK inhibitor was able to abolish the effect of CCh in  $M_3$ -KO bladders (Figure 5F). These results suggest that CCh induces UBSM contractions and RhoA–ROCK activation by both  $M_2$  and  $M_3$  muscarinic receptors and  $M_3$  receptors are apparently able to stimulate UBSM contractions in a RhoA-ROCK-independent manner as well.




**Figure 7 | Gene expression of Rho kinase 1 and 2 (*Rock1*, *Rock2*) in  $M_2$ -,  $M_3$ - and  $M_2/M_3$ -knockout (KO) mice<sup>5</sup>.** A: There was no significant difference in the expression of *Rock1* in wild type (WT) and receptor-deficient animals. B: The mRNA expression of the  $ROCK_2$  was elevated in  $M_2/M_3$ -KO animals compared to that of WT. A: WT:  $n = 8$ ,  $M_2$ -KO:  $n = 5$ ,  $M_3$ -KO:  $n = 6$ ,  $M_2/M_3$ -KO:  $n = 7$ , B: WT:  $n = 8$ ,  $M_2$ -KO:  $n = 5$ ,  $M_3$ -KO:  $n = 6$ ,  $M_2/M_3$ -KO:  $n = 8$ . Kruskal-Wallis test,  $**P < 0.01$ .

<sup>5</sup> Balla, Helga; Borsodi, Kinga; Örsy, Petra; Horváth, Béla; Molnar, Peter J.; Lénárt, Ádám; et al. (2023) Supplemental Material Intracellular signaling pathways of muscarinic acetylcholine receptor-mediated detrusor muscle contractions. figshare. Figure. <https://doi.org/10.6084/m9.figshare.23859108.v1> (150)

### 4.3. Inhibitory effect of pertussis toxin (PTX) on carbamoylcholine (CCh)-induced urinary bladder smooth muscle contraction and RhoA activation

Next, we analyzed the contribution of different heterotrimeric G proteins to CCh-induced RhoA–ROCK activation and UBSM contractions. As  $M_2$  receptors preferentially signal through  $G\alpha_i$ -proteins, we first investigated the effect of PTX, a specific inhibitor of  $G\alpha_i$ , on the UBSM contractions and RhoA activation induced by CCh. The concentration-response curve of CCh was shifted to the right in UBSM strips from WT mice treated with PTX evidenced by the increase of CCh  $EC_{50}$  from  $3.9$  to  $6.5 \times 10^{-7}$  M (Figure 8A). After the demonstration of  $G\alpha_i$ -dependent contraction of CCh, we investigated whether CCh-induced RhoA activation was dependent on  $G\alpha_i$  signaling. In UBSM strips of PTX-treated mice, the RhoA activation induced by CCh was significantly reduced (Figure 8B). Taken together, these results indicate that  $G\alpha_i$ -proteins play an important role in mediating muscarinic agonist-induced RhoA activation and contraction in UBSM.




**Figure 8 | Inhibition of carbamoylcholine (CCh)-induced detrusor muscle contraction and RhoA activation by pertussis toxin (PTX) (150).** A: The concentration-response curve of CCh was shifted to the right in urinary bladder smooth muscle (UBSM) strips from mice treated with PTX without changing the  $E_{max}$  value. B: The CCh ( $3 \times 10^{-5}$  M)-induced RhoA activation was diminished in UBSM strips

from PTX-treated mice. A: CTRL:  $n = 19$ , PTX:  $n = 26$ , B: CTRL:  $n = 4$ , PTX:  $n = 4$ . \*\* $P < 0.01$ . B: Mann-Whitney test, \* $P < 0.05$ .

#### **4.4. $G\alpha_{q/11}$ -coupled signaling pathway plays a key role in urinary bladder contractions but not in RhoA activation induced by carbamoylcholine (CCh)**

Considering our results gained from  $M_3$ -KO animals and the fact that  $M_3$  receptors preferentially couple to  $G\alpha_{q/11}$  (132), we studied the potential involvement of  $G\alpha_{q/11}$ -proteins along with the role of the ROCK enzyme in UBSM contractions and RhoA activation induced by CCh. The concentration-dependent contractions induced by CCh were markedly reduced in UBSM preparations from mice lacking  $G\alpha_{q/11}$  protein ( $EC_{50} = 5.2 \times 10^{-7} M$  vs.  $2.9 \times 10^{-6} M$ ,  $E_{max} = 85.3\%$  vs.  $34.3\%$ ) and were further abolished in the presence of the ROCK inhibitor Y-27632 ( $10 \mu M$ , 20 min) in UBSM deficient in  $G\alpha_{q/11}$  ( $EC_{50} = 6.5 \times 10^{-6} M$ ,  $E_{max} = 18.0\%$ ) (Figure 9A). This observation indicates that  $G\alpha_{q/11}$ -coupled signaling plays a dominant role in muscarinic agonist-induced UBSM contractions. Surprisingly; however, the magnitude of CCh-induced RhoA activation remained unaltered in the absence of  $G\alpha_{q/11}$  signaling (Figure 9B). In summary, these data support the concept that although  $M_3$ -receptor-induced activation of the RhoA–ROCK pathway is involved in UBSM contraction, it is not mediated by  $G\alpha_{q/11}$ , but rather by  $G\alpha_i$ .



**Figure 9 |  $G\alpha_{q/11}$  signaling plays a key role in mediating carbamoylcholine (CCh)-induced bladder contractions but not in RhoA activation (150).** A: Detrusor muscle contractions evoked by CCh were markedly decreased in smooth muscle-specific  $G\alpha_{q/11}$ -knockout (KO) mice and were diminished in the presence of the ROCK inhibitor Y-27632 (10  $\mu$ M) in the  $G\alpha_{q/11}$ -deficient animals. B: CCh ( $3 \times 10^{-5}$  M)-induced RhoA activation was unaffected by the lack of  $G\alpha_{q/11}$  in UBSM. A:  $G\alpha_{q/11}$ -CTRL:  $n = 15$ ,  $G\alpha_{q/11}$ -KO:  $n = 22$ ,  $G\alpha_{q/11}$ -KO + Y-27632:  $n = 8$ , B:  $G\alpha_{q/11}$ -CTRL:  $n = 5$ ,  $G\alpha_{q/11}$ -KO:  $n = 5$ .  $G\alpha_{q/11}$ -CTRL vs  $G\alpha_{q/11}$ -KO: \*\*\*\* $P < 0.0001$ ,  $G\alpha_{q/11}$ -KO vs  $G\alpha_{q/11}$ -KO + Y-27632: #### $P < 0.0001$ . B: Mann-Whitney test,  $P < 0.05$  was considered as significant difference.

## 5. Discussion

OAB is a common clinical condition with the symptoms of frequency, nocturia and urgency with or without incontinence. It significantly impairs the overall quality of life, the performance of daily activities, work, sexual function, sleep and mental health (165-167). About 11-16 % of the population is affected by the symptoms of OAB, although the literature is somewhat controversial on this matter (168-171). In addition, the prevalence of OAB shows a steep increase after the age of 40 years; furthermore, it is prognosticated that over 400 million people will suffer from OAB symptoms in the world's eight major markets by 2030 (172) as a consequence of the aging population (166, 173).

Previously, OAB was suggested to be a nonspecific storage symptom complex without any characteristics of urinary tract infection (174). Even though OAB is considered to be an idiopathic condition, recently several studies proposed its multifaceted pathogenesis. Multiple studies have proposed low-count bacteriuria and inflammation along with the symptoms of OAB (175-178). Moreover, the implication of several pathophysiological factors has been proposed with the occurrence of OAB-like metabolic syndrome (179, 180) and vitamin D deficiency (181); furthermore, detrusor overactivity has been implicated in ovariectomized rats (139, 182).

As muscarinic receptors and the Rho-ROCK pathway play a pivotal role in the regulation of micturition, several studies examined their role and expression levels in animal models of voiding disorders. Tong *et al.* (2007) have demonstrated elevated levels of M<sub>2</sub> and M<sub>3</sub> receptors in the UB of animals suffering from metabolic syndrome (183). Additionally, the expression level of muscarinic receptors has been elevated in obstructed, hypertrophic rat bladders (184). This study has also confirmed the increased contribution of M<sub>2</sub> receptors to detrusor contraction in hypertrophic bladders. Moreover, observations suggested that the ROCK pathway is more privileged in studies of denervated than in normal UBs as inhibition of the ROCK has a greater effect on the concentration-response curve of CCh after bilateral denervation in the rat UB (132). In addition, enhanced enzyme activity has been proposed with aging in human detrusor muscle based on the evidence that the ROCK plays a greater role in the contraction of the detrusor muscle induced by CCh in elderly patients (136). The importance of the

ROCK under pathophysiological conditions is further demonstrated by the fact that per os administration of its specific inhibitor fasudil, relieved the symptoms of detrusor hyperactivity *in vivo* in rats (135).

Given the crucial role of ACh, antimuscarinic drugs are considered to be the mainstay for the treatment of OAB. However, despite the development of bladder selective agents, adherence to the therapy remains a challenge due to the extensive side-effect profile (e.g. dry mouth, obstipation) worsening patients' tolerability (185, 186). Recently, the  $\beta_3$ -AR agonist mirabegron offered an alternative treatment option with an improved side effect profile; however, it seems that it is less effective as compared to antimuscarinics (185, 187).

Earlier observations indicate that muscarinic receptors and the Rho–ROCK pathway are pivotal in detrusor muscle contraction and are associated with the etiology of OAB. Nevertheless, our knowledge of the exact signaling pathways involved in muscarinic receptor-mediated detrusor contractions still remains incomplete. Hence, these examinations incite us to characterize further the signaling pathway of muscarinic receptor activation and detrusor muscle contraction focusing on the role of the RhoA–ROCK pathway for the purpose of providing novel, more specific therapeutic targets for the treatment of bladder dysfunctions.

The CCh-induced UBSM contractions were markedly suppressed in the presence of the ROCK inhibitor Y-27632. These results indicate that the ROCK enzyme has a crucial role in detrusor muscle contractions induced by CCh either in murine and human UB in accordance with previous reports (11, 107).


Furthermore, our goal was to identify the muscarinic receptors that contribute to detrusor muscle contraction and the activation of the RhoA–ROCK pathway in the murine UB. As previous results show that mostly the  $M_2$  and  $M_3$  receptors are present in the mouse UBSM, we focused on the role of these two muscarinic receptor subtypes in the detrusor contractions. Results gained from  $M_2$ -,  $M_3$ - and  $M_2/M_3$ -KO mice show that, in line with the hypothesis, the  $M_2$  and the  $M_3$  muscarinic receptors mediate CCh-induced UBSM contractions simultaneously in the mouse UB indicated by the loss of detrusor muscle contraction in mice lack of either  $M_2$  and  $M_3$  muscarinic receptors. These observations are in accordance with the claims of other groups (65, 188). Therefore, we aimed to examine the role of these two muscarinic receptor subtypes in

the RhoA–ROCK activation in mouse UB. Our findings suggest that RhoA activation is mediated by both the M<sub>2</sub> and the M<sub>3</sub> receptors but no other subtypes in the murine UB based on data gained from M<sub>2</sub>-, M<sub>3</sub>- and M<sub>2</sub>/M<sub>3</sub>-KO animals. In addition, there was no significant difference in the expression levels of the five muscarinic receptor subtypes in the UB strips from M<sub>2</sub>-, M<sub>3</sub>- and M<sub>2</sub>/M<sub>3</sub>-KO mice. Moreover, the expression level of the ROCK<sub>1</sub> was not affected by the gene deletion of M<sub>2</sub> and M<sub>3</sub> receptors; however, the ROCK<sub>2</sub> enzyme manifestation was slightly elevated in double-knockout animals suggesting a compensatory upregulation in the absence of M<sub>2</sub> and M<sub>3</sub> receptors. Previous studies proposed the role of the M<sub>2</sub> receptors in gastrointestinal smooth muscle (188) and UBSM contractions (132); nonetheless, to the best of our knowledge, this is the first study that proves the direct relationship between the M<sub>2</sub> receptor and the RhoA–ROCK pathway in the mouse UB.

It has been suggested that the M<sub>2</sub> and the M<sub>3</sub> receptors are coupled preferentially to G $\alpha_i$  and G $\alpha_{q/11}$  proteins, respectively (56, 58). Therefore, we examined if these G proteins contribute to the activation of RhoA induced by CCh in the mouse detrusor muscle. The concentration-response curve of CCh was shifted to the right after the inhibition of the G $\alpha_i$  by PTX suggesting the involvement of G $\alpha_i$  signaling upon muscarinic receptor activation. Furthermore, the amount of the activated RhoA protein was significantly decreased in PTX-treated animals indicating the direct link between the G $\alpha_i$  and RhoA proteins in the mouse detrusor. The activation of the RhoA protein by G $\alpha_i$  has been investigated previously by other research groups in human airway smooth muscle and HEK-TsA201 cells (189, 190) but this is the first study suggesting the G $\alpha_i$ -dependent RhoA activation in the UBSM.

Finally, we investigated the involvement of the G $\alpha_{q/11}$  protein in CCh-induced contractions and RhoA activation in the UB. CCh-induced detrusor muscle contractions were significantly reduced in the UBSM from mice deficient in G $\alpha_{q/11}$  protein and abolished in the presence of the ROCK inhibitor. These results suggest that the G $\alpha_{q/11}$  protein plays a decisive role in the detrusor contractions induced by CCh. However, contrary to our earlier findings with other mediators (158, 191) and the hypothesized association between the G $\alpha_{q/11}$  and the RhoA–ROCK pathway, the lack of the G $\alpha_{q/11}$  protein did not affect the magnitude of the CCh-induced RhoA activation in the UBSM. Therefore, it appears to be mediated by the G $\alpha_i$  proteins in the murine UB. Based on our

findings,  $M_3$  receptors but not  $G_{\alpha_{q/11}}$  protein are involved in RhoA activation. These results contradict the claims about the conventional wisdom of the exclusive coupling of  $M_3$  receptors to  $G_{\alpha_{q/11}}$  protein. However, Offermanns *et al.* (1994) suggested that the  $M_3$  receptors can also couple to  $G_{\alpha_{i1,3}}$  protein which can explain our results gained from murine UB detrusor strips deficient in  $G_{\alpha_{q/11}}$ -protein (58). In summary, Figure 10 shows our proposed model of muscarinic receptor signaling. The inconsistency between the inhibitory effect of PTX on CCh-induced contractions and RhoA activation can also be explained according to this paradigm. In the presence of PTX, the  $G_{i1}$  and  $G_{i3}$  proteins are inactivated but the fortified  $M_3$ - $G_{\alpha_{q/11}}$  coupling could compensate for the loss of the  $Ca^{2+}$  sensitizing mechanism in detrusor contraction.



**Figure 10 | Proposed model of muscarinic receptor signaling in the murine urinary bladder smooth muscle based on our findings and Offermanns *et al.* (1994) (58, 150).** CaM, calmodulin; MLC, myosin light chain; MLCK, myosin light-chain kinase; MLCP, myosin light-chain phosphatase; ROCK, Rho-associated coiled-coil-containing protein kinase.

There may be some limitations in this study that could be addressed in future research. First of all, neuronal control cannot be investigated *in vitro*, though its importance is unquestionable in the micturition process under physiological as well as pathological conditions. In this context, the role of  $M_2$  receptors in bladder function can

be particularly interesting, as it can modulate sympathetically-mediated relaxant effects by reversing  $\beta$ -adrenoreceptor-mediated detrusor muscle relaxation (192, 193). Furthermore, Igawa *et al.* (2004) have confirmed that the M<sub>3</sub> receptor has a major role in UB contraction in *in vivo* experiments and that noncholinergic mechanisms can compensate for a chronic loss of M<sub>3</sub> receptors (194). Thus, further studies on M<sub>3</sub> receptor-mediated signaling in the bladder under *in vivo* conditions could also contribute significantly to a better understanding of bladder function, as this pathway is still incompletely understood. Besides, as ROCK appears to play an undoubted role in micturition under physiological conditions, addressing the proper dosage of the ROCK inhibitors can be an important concern about their therapeutic usage. However, it has to be mentioned that ROCK inhibitors have been clinically approved to treat glaucoma in oral formulation in Japan without severe adverse effects but hyperaemia (195).

In conclusion, our study contributes to a deeper understanding of the intracellular signaling pathways of muscarinic receptors and the pivotal role of the RhoA–ROCK pathway in detrusor contraction in human and murine UB as well. These data may define a therapeutic potential in the treatment of bladder dysfunctions, including OAB.

## 6. Conclusion

Muscarinic acetylcholine receptors are of utmost importance in the physiological regulation of micturition and also in the development of voiding disorders. Our results gained from the *ex vivo* experiments performed on murine and human UB detrusor strips are the following:

- We demonstrate that the RhoA–ROCK pathway plays a crucial role in contractions induced by cholinergic stimulation in the murine and human detrusor muscle.
- Both  $M_2$  and  $M_3$  receptors mediate the CCh-induced detrusor contractions and the activation of RhoA.
- The muscarinic receptor-mediated RhoA activation is regulated by  $G_i$  but not  $G_{q/11}$  proteins.

The  $G_i$ –Rho–ROCK pathway may provide a novel therapeutic target for overactive voiding disorders.

## 7. Summary

The mAChRs play an unquestionable role in the regulation of micturition and antimuscarinic drugs are mainstays for the treatment of the worldwide symptom complex, OAB. Nevertheless, the exact signaling pathway of mAChRs is obscure even though a more detailed understanding of the signal transduction pathway may help to find more specific drug targets with fewer adverse effects for OAB.

Therefore, in the present study, we aimed to analyze the role of the M<sub>2</sub> and M<sub>3</sub> muscarinic receptors and their corresponding heterotrimeric G proteins (G<sub>i</sub> and G<sub>q/11</sub>, respectively) in the regulation of detrusor function, concentrating on the interaction with the Rho–ROCK pathway. We demonstrated that the ROCK plays a pivotal role in the detrusor contraction induced by the muscarinic receptor agonist, CCh. Moreover, the CCh-induced contractions and RhoA activation are mediated by both the M<sub>2</sub> and the M<sub>3</sub> receptors according to the results gained from M<sub>2</sub>-, M<sub>3</sub>- and M<sub>2</sub>/M<sub>3</sub>-KO animals. In addition, the expression levels of other muscarinic receptors were not altered by the genetic deletion of M<sub>2</sub> and M<sub>3</sub> receptors indicating that no other muscarinic receptors contribute to the UBSM contraction induced by CCh. Furthermore, pharmacological inhibition of the ROCK enzyme had an additional inhibitory effect on the concentration-response curve of CCh in M<sub>2</sub>- and M<sub>3</sub>-KO mice. Interestingly, there was no change in the expression of the ROCK<sub>1</sub> enzyme in detrusor muscle from mice deficient in M<sub>2</sub> or M<sub>3</sub> receptors; however, the ROCK<sub>2</sub> enzyme expression was elevated in M<sub>2</sub>/M<sub>3</sub>-KO mice suggesting a compensatory upregulation of ROCK in the absence of both receptors. PTX treatment of WT mice shifted the concentration-response curve of CCh to the right parallel with a steep decrease in RhoA activation. The CCh-induced contractions were diminished in G<sub>q/11</sub>-KO animals; however, the RhoA activation did not change in mice deficient in G<sub>q/11</sub> compared to that of WT. These results indicate that muscarinic receptor-mediated RhoA activation is not mediated by G<sub>q/11</sub> but rather by G<sub>i</sub>.

These observations can support the development of novel, more specific therapeutic targets that can help to improve patient adherence along with better-tailored therapeutic strategies of OAB to maximize patients' quality of life and cost-effective care.

## 8. References

1. Hill WG. Control of urinary drainage and voiding. *Clinical journal of the American Society of Nephrology : CJASN*. 2015;10(3):480-492.
2. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. *Physiological reviews*. 2004;84(3):935-986.
3. Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. *The Journal of urology*. 2002;168(5):1897-1913.
4. Yoshimura N, De Groat WC. Neural control of the lower urinary tract. *International journal of urology : official journal of the Japanese Urological Association*. 1997;4(2):111-125.
5. Yoshimura N, Kaiho Y, Miyazato M, Yunoki T, Tai C, Chancellor MB, Tyagi P. Therapeutic receptor targets for lower urinary tract dysfunction. *Naunyn-Schmiedeberg's archives of pharmacology*. 2008;377(4-6):437-448.
6. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. *Pharmacological reviews*. 2004;56(4):581-631.
7. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. *British journal of pharmacology*. 2006;147 Suppl 2(Suppl 2):S88-119.
8. Michel MC, Barendrecht MM. Physiological and pathological regulation of the autonomic control of urinary bladder contractility. *Pharmacology & therapeutics*. 2008;117(3):297-312.
9. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. *The Journal of urology*. 2003;170(2 Pt 1):649-653.
10. Frazier EP, Mathy MJ, Peters SL, Michel MC. Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? *The Journal of pharmacology and experimental therapeutics*. 2005;313(1):260-267.
11. Frazier EP, Peters SLM, Braverman AS, Ruggieri MR, Sr., Michel MC. Signal transduction underlying the control of urinary bladder smooth muscle tone by

muscarinic receptors and beta-adrenoceptors. *Naunyn-Schmiedeberg's archives of pharmacology*. 2008;377(4-6):449-462.

12. Philipp M, Brede M, Hein L. Physiological significance of  $\alpha_2$ -adrenergic receptor subtype diversity: one receptor is not enough. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 2002;283(2):R287-R295.

13. Andersson KE, Larsson B, Sjögren C. Characterization of the alpha-adrenoceptors in the female rabbit urethra. *British journal of pharmacology*. 1984;81(2):293-300.

14. Levin RM, Ruggieri MR, Wein AJ. Identification of receptor subtypes in the rabbit and human urinary bladder by selective radio-ligand binding. *The Journal of urology*. 1988;139(4):844-848.

15. Latifpour J, Kondo S, O'hollaren B, Morita T, Weiss RM. Autonomic receptors in urinary tract: sex and age differences. *The Journal of pharmacology and experimental therapeutics*. 1990;253(2):661-667.

16. Goepel M, Wittmann A, Rübben H, Michel MC. Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. *Urological research*. 1997;25(3):199-206.

17. Santicioli P, Maggi CA, Meli A. The effects of clonidine on electrically-induced contractions of rat detrusor strips in vitro. *Journal of autonomic pharmacology*. 1983;3(3):161-166.

18. Maggi CA, Santicioli P, Furio M, Meli A. Dual effects of clonidine on micturition reflex in urethane anesthetized rats. *The Journal of pharmacology and experimental therapeutics*. 1985;235(2):528-536.

19. Tsurusaki M, Yoshida M, Akasu T, Nagatsu I. Alpha 2-adrenoceptors mediate the inhibition of cholinergic transmission in parasympathetic ganglia of the rabbit urinary bladder. *Synapse*. 1990;5(3):233-240.

20. Nakamura T, Yoshimura M, Shinnick-Gallagher P, Gallagher JP, Akasu T. alpha 2 and alpha 1-Adrenoceptors mediate opposing actions on parasympathetic neurons. *Brain Res*. 1984;323(2):349-353.

21. Harada T, Constantinou CE. The effect of alpha 2 agonists and antagonists on the lower urinary tract of the rat. *The Journal of urology*. 1993;149(1):159-164.

22. Perlberg S, Caine M. Adrenergic response of bladder muscle in prostatic obstruction. Its relation to detrusor instability. *Urology*. 1982;20(5):524-527.
23. Sundin T, Dahlström A. The sympathetic innervation of the urinary bladder and urethra in the normal state and after parasympathetic denervation at the spinal root level. An experimental study in cats. *Scand J Urol Nephrol*. 1973;7(2):131-149.
24. Rohner TJ, Hannigan JD, Sanford EJ. Altered in vitro adrenergic responses of dog detrusor muscle after chronic bladder outlet obstruction. *Urology*. 1978;11(4):357-361.
25. Tsujii T, Azuma H, Yamaguchi T, Oshima H. A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia. *British journal of pharmacology*. 1992;107(3):803-807.
26. Keast JR, Smith-Anttila CJ, Osborne PB. Developing a functional urinary bladder: a neuronal context. *Frontiers in cell and developmental biology*. 2015;3:53.
27. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. *Autonomic & autacoid pharmacology*. 2002;22(3):133-145.
28. Caulfield MP. Muscarinic receptors--characterization, coupling and function. *Pharmacology & therapeutics*. 1993;58(3):319-379.
29. Kruse AC, Hu J, Pan AC, Arlow DH, Rosenbaum DM, Rosemond E, Green HF, Liu T, Chae PS, Dror RO, Shaw DE, Weis WI, Wess J, Kobilka BK. Structure and dynamics of the M3 muscarinic acetylcholine receptor. *Nature*. 2012;482(7386):552-556.
30. Hulme EC, Birdsall NJ, Buckley NJ. Muscarinic receptor subtypes. *Annual review of pharmacology and toxicology*. 1990;30:633-673.
31. Wess J. Molecular biology of muscarinic acetylcholine receptors. *Critical reviews in neurobiology*. 1996;10(1):69-99.
32. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. *Pharmacological reviews*. 1998;50(2):279-290.
33. Inadome A, Yoshida M, Takahashi W, Yono M, Seshita H, Miyamoto Y, Kawano T, Ueda S. Prejunctional Muscarinic Receptors Modulating Acetylcholine

Release in Rabbit Detrusor Smooth Muscles. *Urologia internationalis*. 1998;61(3):135-141.

34. D'agostino G, Bolognesi ML, Lucchelli A, Vicini D, Balestra B, Spelta V, Melchiorre C, Tonini M. Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of the M4 receptor subtype. *British journal of pharmacology*. 2000;129(3):493-500.

35. Takeuchi T, Yamashiro N, Kawasaki T, Nakajima H, Azuma YT, Matsui M. The role of muscarinic receptor subtypes in acetylcholine release from urinary bladder obtained from muscarinic receptor knockout mouse. *Neuroscience*. 2008;156(2):381-389.

36. Tyagi S, Tyagi P, Van-Le S, Yoshimura N, Chancellor MB, De Miguel F. Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. *The Journal of urology*. 2006;176(4 Pt 1):1673-1678.

37. Tong YC, Cheng JT, Hsu CT. Alterations of M(2)-muscarinic receptor protein and mRNA expression in the urothelium and muscle layer of the streptozotocin-induced diabetic rat urinary bladder. *Neuroscience letters*. 2006;406(3):216-221.

38. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. *British journal of pharmacology*. 2005;144(8):1089-1099.

39. Zarghooni S, Wunsch J, Bodenbenner M, Brüggmann D, Grando SA, Schwantes U, Wess J, Kummer W, Lips KS. Expression of muscarinic and nicotinic acetylcholine receptors in the mouse urothelium. *Life sciences*. 2007;80(24-25):2308-2313.

40. Bschleipfer T, Schukowski K, Weidner W, Grando SA, Schwantes U, Kummer W, Lips KS. Expression and distribution of cholinergic receptors in the human urothelium. *Life sciences*. 2007;80(24-25):2303-2307.

41. Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V, Anand P. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. *The Journal of urology*. 2006;176(1):367-373.

42. Abrams P, Andersson K-E, Buccafusco JJ, Chapple C, De Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ. Muscarinic receptors: their

distribution and function in body systems, and the implications for treating overactive bladder. 2006;148(5):565-578.

43. Sigala S, Mirabella G, Peroni A, Pezzotti G, Simeone C, Spano P, Cunico SC. Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. *Urology*. 2002;60(4):719-725.

44. Yamaguchi O, Shishido K, Tamura K, Ogawa T, Fujimura T, Ohtsuka M. Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. *The Journal of urology*. 1996;156(3):1208-1213.

45. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. *The Journal of pharmacology and experimental therapeutics*. 1995;273(2):959-966.

46. Yamanishi T, Chapple CR, Yasuda K, Chess-Williams R. The role of M2 muscarinic receptor subtypes in mediating contraction of the pig bladder base after cyclic adenosine monophosphate elevation and/or selective M3 inactivation. *The Journal of urology*. 2002;167(1):397-401.

47. Bahadory F, Moore K, Liu L, Burcher E. Gene expression of muscarinic, tachykinin, and purinergic receptors in porcine bladder: comparison with cultured cells. 2013;4.

48. Eglen RM, Reddy H, Watson N, Challiss RA. Muscarinic acetylcholine receptor subtypes in smooth muscle. *Trends in pharmacological sciences*. 1994;15(4):114-119.

49. Stengel PW, Gomeza J, Wess J, Cohen ML. M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. *The Journal of pharmacology and experimental therapeutics*. 2000;292(3):877-885.

50. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. *British journal of pharmacology*. 2006;147 Suppl 2(Suppl 2):S80-87.

51. Weber S, Thiele H, Mir S, Toliat MR, Sozeri B, Reutter H, Draaken M, Ludwig M, Altmüller J, Frommolt P, Stuart HM, Ranjzad P, Hanley NA, Jennings R, Newman WG, Wilcox DT, Thiel U, Schlingmann KP, Beetz R, Hoyer PF, Konrad M, Schaefer F, Nürnberg P, Woolf AS. Muscarinic Acetylcholine Receptor M3 Mutation Causes Urinary Bladder Disease and a Prune-Belly-like Syndrome. *American journal of human genetics*. 2011;89(5):668-674.

52. Juan YS, Chuang SM, Long CY, Chen CH, Levin RM, Liu KM, Huang CH. Neuroprotection of green tea catechins on surgical menopause-induced overactive bladder in a rat model. *Menopause* (New York, NY). 2012;19(3):346-354.
53. Long CY, Hsu CS, Shao PL, Liu CM, Su JH, Tsai EM. Effect of ovariectomy on the gene expression of detrusor muscarinic receptors in female rats. *Fertility and sterility*. 2009;92(3):1147-1149.
54. Lee K-C. Changes of muscarinic receptors and connexin-43 expression as a mechanism of overactive bladder in ovariectomized rats. *World journal of urology*. 2015;33(11):1875-1879.
55. Pontari MA, Braverman AS, Ruggieri MR, Sr. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. *American journal of physiology Regulatory, integrative and comparative physiology*. 2004;286(5):R874-880.
56. Haga T. Molecular properties of muscarinic acetylcholine receptors. *Proceedings of the Japan Academy, Series B*. 2013;89(6):226-256.
57. Robinson D, O'kane M, Cardozo L. Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives. *International journal of women's health*. 2023;15:799-811.
58. Offermanns S, Wieland T, Homann D, Sandmann J, Bombien E, Spicher K, Schultz G, Jakobs KH. Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq/11. *Molecular pharmacology*. 1994;45(5):890-898.
59. Komolov KE, Du Y, Duc NM, Betz RM, Rodrigues J, Leib RD, Patra D, Skiniotis G, Adams CM, Dror RO, Chung KY, Kobilka BK, Benovic JL. Structural and Functional Analysis of a  $\beta(2)$ -Adrenergic Receptor Complex with GRK5. *Cell*. 2017;169(3):407-421.e416.
60. Weis WI, Kobilka BK. The Molecular Basis of G Protein-Coupled Receptor Activation. *Annual review of biochemistry*. 2018;87:897-919.
61. Syrovatkina V, Alegre KO, Dey R, Huang XY. Regulation, Signaling, and Physiological Functions of G-Proteins. *Journal of molecular biology*. 2016;428(19):3850-3868.
62. Wilkie TM, Scherle PA, Strathmann MP, Slepak VZ, Simon MI. Characterization of G-protein alpha subunits in the Gq class: expression in murine

tissues and in stromal and hematopoietic cell lines. *Proceedings of the National Academy of Sciences of the United States of America*. 1991;88(22):10049-10053.

63. Strathmann M, Simon MI. G protein diversity: a distinct class of alpha subunits is present in vertebrates and invertebrates. *Proceedings of the National Academy of Sciences of the United States of America*. 1990;87(23):9113-9117.

64. Kamato D, Thach L, Bernard R, Chan V, Zheng W, Kaur H, Brimble M, Osman N, Little PJ. Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein,  $G\alpha/q$ . 2015;2.

65. Braverman AS, Tibb AS, Ruggieri MR, Sr. M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder. *The Journal of pharmacology and experimental therapeutics*. 2006;316(2):869-874.

66. Billington CK, Penn RB. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. *Respiratory research*. 2003;4(1):2.

67. Chiba Y, Sakai H, Misawa M. Possible involvement of  $G(i3)$  protein in augmented contraction of bronchial smooth muscle from antigen-induced airway hyperresponsive rats. *Biochemical pharmacology*. 2001;61(7):921-924.

68. Rebres RA, Roach TI, Fraser ID, Philip F, Moon C, Lin KM, Liu J, Santat L, Cheadle L, Ross EM, Simon MI, Seaman WE. Synergistic  $Ca^{2+}$  responses by  $G\{\alpha\}i$ - and  $G\{\alpha\}q$ -coupled G-protein-coupled receptors require a single  $PLC\{\beta\}$  isoform that is sensitive to both  $G\{\beta\}\{\gamma\}$  and  $G\{\alpha\}q$ . *The Journal of biological chemistry*. 2011;286(2):942-951.

69. Pfeil EM, Brands J, Merten N, Vögtle T, Vescovo M, Rick U, Albrecht I-M, Heycke N, Kawakami K, Ono Y, Ngako Kadji FM, Hiratsuka S, Aoki J, Häberlein F, Matthey M, Garg J, Hennen S, Jobin M-L, Seier K, Calebiro D, Pfeifer A, Heinemann A, Wenzel D, König GM, Nieswandt B, Fleischmann BK, Inoue A, Simon K, Kostenis E. Heterotrimeric G Protein Subunit  $G\alpha q$  Is a Master Switch for  $G\beta\gamma$ -Mediated Calcium Mobilization by  $G_i$ -Coupled GPCRs. *Molecular Cell*. 2020;80(6):940-954.e946.

70. Yang CF, Tsai WC. Calmodulin: The switch button of calcium signaling. *Tzu chi medical journal*. 2022;34(1):15-22.

71. Carafoli E, Krebs J. Why Calcium? How Calcium Became the Best Communicator. *The Journal of biological chemistry*. 2016;291(40):20849-20857.

72. Clapham DE. Calcium signaling. *Cell*. 2007;131(6):1047-1058.

73. Swulius MT, Waxham MN. Ca(2+)/calmodulin-dependent protein kinases. *Cellular and molecular life sciences : CMLS*. 2008;65(17):2637-2657.
74. Kishi H, Ye LH, Nakamura A, Okagaki T, Iwata A, Tanaka T, Kohama K. Structure and function of smooth muscle myosin light chain kinase. *Advances in experimental medicine and biology*. 1998;453:229-234.
75. Anjum I. Calcium sensitization mechanisms in detrusor smooth muscles. *Journal of basic and clinical physiology and pharmacology*. 2018;29(3):227-235.
76. Álvarez-Santos MD, Álvarez-González M, Estrada-Soto S, Bazán-Perkins B. Regulation of Myosin Light-Chain Phosphatase Activity to Generate Airway Smooth Muscle Hypercontractility. 2020;11.
77. Berridge MJ. Smooth muscle cell calcium activation mechanisms. *The Journal of physiology*. 2008;586(21):5047-5061.
78. Hill-Eubanks DC, Werner ME, Heppner TJ, Nelson MT. Calcium signaling in smooth muscle. *Cold Spring Harbor perspectives in biology*. 2011;3(9):a004549.
79. Shirazi A, Iizuka K, Fadden P, Mosse C, Somlyo AP, Somlyo AV, Haystead TA. Purification and characterization of the mammalian myosin light chain phosphatase holoenzyme. The differential effects of the holoenzyme and its subunits on smooth muscle. *The Journal of biological chemistry*. 1994;269(50):31598-31606.
80. Kitazawa T, Kobayashi S, Horiuti K, Somlyo AV, Somlyo AP. Receptor-coupled, permeabilized smooth muscle. Role of the phosphatidylinositol cascade, G-proteins, and modulation of the contractile response to Ca<sup>2+</sup>. *The Journal of biological chemistry*. 1989;264(10):5339-5342.
81. Jaggar JH, Porter VA, Lederer WJ, Nelson MT. Calcium sparks in smooth muscle. 2000;278(2):C235-C256.
82. Iino M. Molecular basis and physiological functions of dynamic Ca<sup>2+</sup> signalling in smooth muscle cells. *Novartis Foundation symposium*. 2002;246:142-146; discussion 147-153, 221-147.
83. Bonev AD, Jaggar JH, Rubart M, Nelson MT. Activators of protein kinase C decrease Ca<sup>2+</sup> spark frequency in smooth muscle cells from cerebral arteries. *The American journal of physiology*. 1997;273(6):C2090-2095.

84. Somlyo AP, Somlyo AV. Ca<sup>2+</sup> sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. *Physiological reviews*. 2003;83(4):1325-1358.
85. Bremerich DH, Warner DO, Lorenz RR, Shumway R, Jones KA. Role of protein kinase C in calcium sensitization during muscarinic stimulation in airway smooth muscle. 1997;273(4):L775-L781.
86. Yang G, Li T, Xu J, Liu L. PKC plays an important mediated effect in arginine vasopressin induced restoration of vascular responsiveness and calcium sensitization following hemorrhagic shock in rats. *European journal of pharmacology*. 2010;628(1):148-154.
87. Oishi K, Mita M, Ono T, Hashimoto T, Uchida MK. Protein kinase C-independent sensitization of contractile proteins to Ca<sup>2+</sup> in alpha-toxin-permeabilized smooth muscle cells from the guinea-pig stomach. *British journal of pharmacology*. 1992;107(4):908-909.
88. Hori M, Sato K, Miyamoto S, Ozaki H, Karaki H. Different pathways of calcium sensitization activated by receptor agonists and phorbol esters in vascular smooth muscle. *British journal of pharmacology*. 1993;110(4):1527-1531.
89. Fujita A, Takeuchi T, Nakajima H, Nishio H, Hata F. Involvement of heterotrimeric GTP-binding protein and rho protein, but not protein kinase C, in agonist-induced Ca<sup>2+</sup> sensitization of skinned muscle of guinea pig vas deferens. *The Journal of pharmacology and experimental therapeutics*. 1995;274(1):555-561.
90. Gong MC, Gorenne I, Read P, Jia T, Nakamoto RK, Somlyo AV, Somlyo AP. Regulation by GDI of RhoA/Rho-kinase-induced Ca<sup>2+</sup> sensitization of smooth muscle myosin II. *American journal of physiology Cell physiology*. 2001;281(1):C257-269.
91. Gong MC, Iizuka K, Nixon G, Browne JP, Hall A, Eccleston JF, Sugai M, Kobayashi S, Somlyo AV, Somlyo AP. Role of guanine nucleotide-binding proteins--ras-family or trimeric proteins or both--in Ca<sup>2+</sup> sensitization of smooth muscle. *Proceedings of the National Academy of Sciences of the United States of America*. 1996;93(3):1340-1345.
92. Hirata K, Kikuchi A, Sasaki T, Kuroda S, Kaibuchi K, Matsuura Y, Seki H, Saida K, Takai Y. Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity

of smooth muscle contraction. *The Journal of biological chemistry*. 1992;267(13):8719-8722.

93. Itagaki M, Komori S, Unno T, Syuto B, Ohashi H. Possible involvement of a small G-protein sensitive to exoenzyme C3 of *Clostridium botulinum* in the regulation of myofilament Ca<sup>2+</sup> sensitivity in beta-escin skinned smooth muscle of guinea pig ileum. *Japanese journal of pharmacology*. 1995;67(1):1-7.

94. Loirand G, Cario-Toumaniantz C, Chardin P, Pacaud P. The Rho-related protein Rnd1 inhibits Ca<sup>2+</sup> sensitization of rat smooth muscle. *The Journal of physiology*. 1999;516 ( Pt 3)(Pt 3):825-834.

95. Noda M, Yasuda-Fukazawa C, Moriishi K, Kato T, Okuda T, Kurokawa K, Takuwa Y. Involvement of rho in GTP gamma S-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells: inhibition of phosphatase activity. *FEBS letters*. 1995;367(3):246-250.

96. Otto B, Steusloff A, Just I, Aktories K, Pfitzer G. Role of Rho proteins in carbachol-induced contractions in intact and permeabilized guinea-pig intestinal smooth muscle. *The Journal of physiology*. 1996;496 ( Pt 2)(Pt 2):317-329.

97. Takeuchi T, Kushida M, Hirayama N, Kitayama M, Fujita A, Hata F. Mechanisms involved in carbachol-induced Ca(2+) sensitization of contractile elements in rat proximal and distal colon. *British journal of pharmacology*. 2004;142(4):657-666.

98. Lucius C, Arner A, Steusloff A, Troschka M, Hofmann F, Aktories K, Pfitzer G. *Clostridium difficile* toxin B inhibits carbachol-induced force and myosin light chain phosphorylation in guinea-pig smooth muscle: role of Rho proteins. *The Journal of physiology*. 1998;506 ( Pt 1)(Pt 1):83-93.

99. Fujihara H, Walker LA, Gong MC, Lemichez E, Boquet P, Somlyo AV, Somlyo AP. Inhibition of RhoA translocation and calcium sensitization by in vivo ADP-ribosylation with the chimeric toxin DC3B. *Molecular biology of the cell*. 1997;8(12):2437-2447.

100. Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. *The Journal of biological chemistry*. 2003;278(11):9472-9480.

101. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. *Cell*. 2007;129(5):865-877.

102. Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. *The Biochemical journal*. 2005;390(Pt 1):1-9.
103. Schmandke A, Schmandke A, Strittmatter SM. ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. *The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry*. 2007;13(5):454-469.
104. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. *The Journal of biological chemistry*. 1995;270(49):29051-29054.
105. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. *The EMBO journal*. 1996;15(9):2208-2216.
106. Fujisawa K, Fujita A, Ishizaki T, Saito Y, Narumiya S. Identification of the Rho-binding domain of p160ROCK, a Rho-associated coiled-coil containing protein kinase. *The Journal of biological chemistry*. 1996;271(38):23022-23028.
107. Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. *British journal of pharmacology*. 2003;138(5):757-766.
108. Chang S, Hypolite JA, Disanto ME, Changolkar A, Wein AJ, Chacko S. Increased basal phosphorylation of detrusor smooth muscle myosin in alloxan-induced diabetic rabbit is mediated by upregulation of Rho-kinase beta and CPI-17. *Am J Physiol Renal Physiol*. 2006;290(3):F650-656.
109. Takahashi R, Nishimura J, Hirano K, Seki N, Naito S, Kanaide H. Ca<sup>2+</sup> sensitization in contraction of human bladder smooth muscle. *The Journal of urology*. 2004;172(2):748-752.
110. Proud CG. A sharper instrument for dissecting signalling events: a specific AGC kinase inhibitor. *The Biochemical journal*. 2007;401(1):e1-3.
111. Riento K, Guasch RM, Garg R, Jin B, Ridley AJ. RhoE Binds to ROCK I and Inhibits Downstream Signaling. *Molecular and cellular biology*. 2003;23(12):4219-4229.
112. Amano M, Nakayama M, Kaibuchi K. Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. *Cytoskeleton (Hoboken, NJ)*. 2010;67(9):545-554.

113. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science (New York, NY)*. 1996;273(5272):245-248.
114. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). *The Journal of biological chemistry*. 1996;271(34):20246-20249.
115. Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F. Distinct Roles of Rock (Rho-Kinase) and Mlck in Spatial Regulation of Mlc Phosphorylation for Assembly of Stress Fibers and Focal Adhesions in 3t3 Fibroblasts. *Journal of Cell Biology*. 2000;150(4):797-806.
116. Mori K, Amano M, Takefuji M, Kato K, Morita Y, Nishioka T, Matsuura Y, Murohara T, Kaibuchi K. Rho-kinase contributes to sustained RhoA activation through phosphorylation of p190A RhoGAP. *The Journal of biological chemistry*. 2009;284(8):5067-5076.
117. Sato A, Hattori Y, Sasaki M, Tomita F, Kohya T, Kitabatake A, Kanno M. Agonist-dependent difference in the mechanisms involved in Ca<sup>2+</sup> sensitization of smooth muscle of porcine coronary artery. *Journal of cardiovascular pharmacology*. 2000;35(5):814-821.
118. Puetz S, Lubomirov LT, Pfitzer G. Regulation of Smooth Muscle Contraction by Small GTPases. 2009;24(6):342-356.
119. González-Forero D, Montero F, García-Morales V, Domínguez G, Gómez-Pérez L, García-Verdugo JM, Moreno-López B. Endogenous Rho-kinase signaling maintains synaptic strength by stabilizing the size of the readily releasable pool of synaptic vesicles. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012;32(1):68-84.
120. Hou Y, Zhou L, Yang QD, Du XP, Li M, Yuan M, Zhou ZW. Changes in hippocampal synapses and learning-memory abilities in a streptozotocin-treated rat model and intervention by using fasudil hydrochloride. *Neuroscience*. 2012;200:120-129.
121. Raad M, El Tal T, Gul R, Mondello S, Zhang Z, Boustany RM, Guingab J, Wang KK, Kobeissy F. Neuroproteomics approach and neurosystems biology analysis:

ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma. *Electrophoresis*. 2012;33(24):3659-3668.

122. Villar-Cheda B, Dominguez-Meijide A, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. *Neurobiology of disease*. 2012;47(2):268-279.

123. Tönges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego É M, Bähr M, Weishaupt JH, Lingor P. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. *Brain : a journal of neurology*. 2012;135(Pt 11):3355-3370.

124. Inan S, Büyükafşar K. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. *British journal of pharmacology*. 2008;155(1):44-51.

125. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, Yu CM. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. *Drug discovery today*. 2010;15(15-16):622-629.

126. Li Q, Chen Y, Sun L, Fu G, Guo L. Vasodilatation produced by fasudil mesylate in vivo and in vitro. *Vascular pharmacology*. 2011;55(5-6):121-126.

127. Mahavadi S, Sriwai W, Manion O, Grider JR, Murthy KS. Diabetes-induced oxidative stress mediates upregulation of RhoA/Rho kinase pathway and hypercontractility of gastric smooth muscle. *PloS one*. 2017;12(7):e0178574.

128. Chacko S, Chang S, Hypolite J, Disanto M, Wein A. Alteration of contractile and regulatory proteins following partial bladder outlet obstruction. *Scandinavian journal of urology and nephrology Supplementum*. 2004(215):26-36.

129. Bing W, Chang S, Hypolite JA, Disanto ME, Zderic SA, Rolf L, Wein AJ, Chacko S. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. *Am J Physiol Renal Physiol*. 2003;285(5):F990-997.

130. Su X, Changolkar A, Chacko S, Moreland RS. Diabetes decreases rabbit bladder smooth muscle contraction while increasing levels of myosin light chain phosphorylation. *Am J Physiol Renal Physiol*. 2004;287(4):F690-699.

131. Rajasekaran M, Wilkes N, Kuntz S, M EA. Rho-kinase inhibition suppresses bladder hyperactivity in spontaneously hypertensive rats. *Neurourology and urodynamics*. 2005;24(3):295-300.

132. Braverman AS, Doumanian LR, Ruggieri MR, Sr. M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder. *The Journal of pharmacology and experimental therapeutics*. 2006;316(2):875-880.
133. Masago T, Watanabe T, Saito M, Kinoshita Y, Sato K, Miyagawa I. Effect of the rho-kinase inhibitor hydroxyfasudil on bladder overactivity: An experimental rat model. *International Journal of Urology*. 2009;16(10):842-847.
134. Denizalti M, Durlu-Kandilci NT, Simsek G, Bozkurt TE, Sahin-Erdemli I. Rho Kinase and Protein Kinase C Pathways are Responsible for Enhanced Carbachol Contraction in Permeabilized Detrusor in a Rat Model of Cystitis. *Basic & clinical pharmacology & toxicology*. 2018;123(5):567-576.
135. Kim JY, Han JY, Kwon TG, Choo MS. Effects of Oral Rho Kinase Inhibitor Fasudil on Detrusor Overactivity after Bladder Outlet Obstruction in Rats. *Lower urinary tract symptoms*. 2013;5(2):96-100.
136. Kirschstein T, Protzel C, Porath K, Sellmann T, Köhling R, Hakenberg OW. Age-dependent contribution of Rho kinase in carbachol-induced contraction of human detrusor smooth muscle in vitro. *Acta pharmacologica Sinica*. 2014;35(1):74-81.
137. Kirschstein T, Sahre T, Kernig K, Protzel C, Porath K, Köhling R, Hakenberg OW. Inverse relationship of Rho kinase and myosin-light chain kinase expression in the aging human detrusor smooth muscle. *BMC urology*. 2015;15:104.
138. Hong SK, Yang JH, Kim TB, Kim SW, Paick JS. Effects of ovariectomy and oestrogen replacement on the function and expression of Rho-kinase in rat bladder smooth muscle. *BJU international*. 2006;98(5):1114-1117.
139. Wróbel A, Rechberger T. Ovariectomy May Induce Detrusor Overactivity in Rats: The Therapeutic Role of Rho Kinase Inhibition. *Urology*. 2016;93:225.e221-227.
140. Robinson D, Cardozo L, Milsom I, Pons ME, Kirby M, Koelbl H, Vierhout M. Oestrogens and overactive bladder. *Neurourology and urodynamics*. 2014;33(7):1086-1091.
141. Cardozo L, Lisek M, Millard R, Van Vierssen Trip O, Kuzmin I, Drogendijk TE, Huang M, Ridder AM. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. *The Journal of urology*. 2004;172(5 Pt 1):1919-1924.

142. Wettschureck N, Rütten H, Zywiets A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpa11 in cardiomyocytes. *Nature medicine*. 2001;7(11):1236-1240.
143. Indra AK, Warot X, Brocard J, Bornert J-M, Xiao J-H, Chambon P, Metzger D. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ERT and Cre-ERT2 recombinases. *Nucleic acids research*. 1999;27(22):4324-4327.
144. Dér B, Molnár PJ, Ruisanchez É, Órsy P, Kerék M, Faragó B, Nyirády P, Offermanns S, Benyó Z. NK2 receptor-mediated detrusor muscle contraction involves G(q/11)-dependent activation of voltage-dependent Ca(2+) channels and the RhoA-Rho kinase pathway. *Am J Physiol Renal Physiol*. 2019;317(5):F1154-f1163.
145. Mangmool S, Kurose H. G(i/o) protein-dependent and -independent actions of Pertussis Toxin (PTX). *Toxins*. 2011;3(7):884-899.
146. Ivanics T, Miklós Z, Dézsi L, Ikrényi K, Tóth A, Roemen THM, Van Der Vusse GJ, Li Geti L. Concomitant accumulation of intracellular free calcium and arachidonic acid in the ischemic-reperfused rat heart. *Molecular and Cellular Biochemistry*. 2001;226(1):119-128.
147. Nakahara T, Kubota Y, Mitani A, Maruko T, Sakamoto K, Ishii K. Protease-activated receptor-2-mediated contraction in the rat urinary bladder: the role of urinary bladder mucosa. *Naunyn-Schmiedeberg's archives of pharmacology*. 2003;367(2):211-213.
148. Masick JM, Levin RM, Hass MA. The effect of partial outlet obstruction on prostaglandin generation in the rabbit urinary bladder. *Prostaglandins & other lipid mediators*. 2001;66(3):211-219.
149. Erdogan BR, Karaomerlioglu I, Yesilyurt ZE, Ozturk N, Muderrisoglu AE, Michel MC, Arioglu-Inan E. Normalization of organ bath contraction data for tissue specimen size: does one approach fit all? *Naunyn-Schmiedeberg's archives of pharmacology*. 2020;393(2):243-251.
150. Balla H, Borsodi K, Órsy P, Horváth B, Molnár PJ, Lénárt Á, Kosztelnik M, Ruisanchez É, Wess J, Offermanns S, Nyirády P, Benyó Z. Intracellular signaling

pathways of muscarinic acetylcholine receptor-mediated detrusor muscle contractions. *Am J Physiol Renal Physiol*. 2023;325(5):F618-f628.

151. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG. Primer3--new capabilities and interfaces. *Nucleic acids research*. 2012;40(15):e115.

152. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. *BMC bioinformatics*. 2012;13:134.

153. Niwa Y, Kanda GN, Yamada RG, Shi S, Sunagawa GA, Ukai-Tadenuma M, Fujishima H, Matsumoto N, Masumoto KH, Nagano M, Kasukawa T, Galloway J, Perrin D, Shigeyoshi Y, Ukai H, Kiyonari H, Sumiyama K, Ueda HR. Muscarinic Acetylcholine Receptors Chrm1 and Chrm3 Are Essential for REM Sleep. *Cell reports*. 2018;24(9):2231-2247.e2237.

154. Kistemaker LE, Bos IS, Hylkema MN, Nawijn MC, Hiemstra PS, Wess J, Meurs H, Kerstjens HA, Gosens R. Muscarinic receptor subtype-specific effects on cigarette smoke-induced inflammation in mice. *The European respiratory journal*. 2013;42(6):1677-1688.

155. Thomson SR, Seo SS, Barnes SA, Louros SR, Muscas M, Dando O, Kirby C, Wyllie DJA, Hardingham GE, Kind PC, Osterweil EK. Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome. *Neuron*. 2017;95(3):550-563.e555.

156. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic acids research*. 2001;29(9):e45.

157. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clinical chemistry*. 2009;55(4):611-622.

158. Borsodi K, Balla H, Molnar PJ, Lenart A, Kenessey I, Horvath A, Keszthelyi A, Romics M, Majoros A, Nyirady P, Offermanns S, Benyo Z. Signaling Pathways Mediating Bradykinin-Induced Contraction in Murine and Human Detrusor Muscle. *Frontiers in medicine*. 2021;8:745638.

159. Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. *Pharmacology*. 2009;83(5):259-269.

160. Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodtkin J, Grinberg A, Sheng H, Wess J. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. *Proceedings of the National Academy of Sciences of the United States of America*. 1999;96(4):1692-1697.
161. Fisahn A, Yamada M, Duttaroy A, Gan JW, Deng CX, Mcbain CJ, Wess J. Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. *NEURON*. 2002;33(4):615-624.
162. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodtkin J, Shannon H, Xia B, Deng CX, Wess J. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M-4 muscarinic acetylcholine receptor knockout mice. *Proceedings of the National Academy of Sciences of the United States of America*. 1999;96(18):10483-10488.
163. Hamilton SE, Loose MD, Qi M, Levey AI, Hille B, Mcknight GS, Idzerda RL, Nathanson NM. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. *Proceedings of the National Academy of Sciences of the United States of America*. 1997;94(24):13311-13316.
164. Miyakawa T, Yamada M, Duttaroy A, Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M-1 muscarinic acetylcholine receptor. *JOURNAL OF NEUROSCIENCE*. 2001;21(14):5239-5250.
165. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. *The American journal of managed care*. 2000;6(11 Suppl):S580-590.
166. Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. *Research and reports in urology*. 2016;8:71-76.
167. Coyne KS, Kaplan SA, Chapple CR, Sexton CC, Kopp ZS, Bush EN, Aiyer LP. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. *BJU international*. 2009;103 Suppl 3:24-32.
168. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. *BJU international*. 2001;87(9):760-766.

169. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. *Urology*. 2011;77(5):1081-1087.
170. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *European urology*. 2006;50(6):1306-1314; discussion 1314-1305.
171. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. *World journal of urology*. 2003;20(6):327-336.
172. Babin CP, Catalano NT, Yancey DM, Pearl NZ, Koonce EM, Ahmadzadeh S, Shekoohi S, Cornett EM, Kaye AD. Update on Overactive Bladder Therapeutic Options. *American journal of therapeutics*. 2023.
173. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. *BJU international*. 2011;108(7):1132-1138.
174. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. *Urology*. 2002;60(5, Supplement 1):7-12.
175. Moore KH, Simons A, Mukerjee C, Lynch W. The relative incidence of detrusor instability and bacterial cystitis detected on the urodynamic-test day. *BJU international*. 2000;85(7):786-792.
176. Chen Z, Phan MD, Bates LJ, Peters KM, Mukerjee C, Moore KH, Schembri MA. The urinary microbiome in patients with refractory urge incontinence and recurrent urinary tract infection. *Int Urogynecol J*. 2018;29(12):1775-1782.
177. Khasriya R, Sathiananthamoorthy S, Ismail S, Kelsey M, Wilson M, Rohn JL, Malone-Lee J. Spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms. *J Clin Microbiol*. 2013;51(7):2054-2062.
178. Walsh CA, Moore KH. Overactive bladder in women: does low-count bacteriuria matter? A review. *Neurourology and urodynamics*. 2011;30(1):32-37.

179. He Q, Wang Z, Liu G, Daneshgari F, Maclennan GT, Gupta S. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. *Prostate cancer and prostatic diseases*. 2016;19(1):7-13.
180. Hsu LN, Hu JC, Chen PY, Lee WC, Chuang YC. Metabolic Syndrome and Overactive Bladder Syndrome May Share Common Pathophysiologies. *Biomedicines*. 2022;10(8).
181. Vaughan CP, Johnson TM, 2nd, Goode PS, Redden DT, Burgio KL, Markland AD. Vitamin D and lower urinary tract symptoms among US men: results from the 2005-2006 National Health and Nutrition Examination Survey. *Urology*. 2011;78(6):1292-1297.
182. Yoshida J, Aikawa K, Yoshimura Y, Shishido K, Yanagida T, Yamaguchi O. The effects of ovariectomy and estrogen replacement on acetylcholine release from nerve fibres and passive stretch-induced acetylcholine release in female rat bladder. *Neurourology and urodynamics*. 2007;26(7):1050-1055.
183. Tong YC, Cheng JT. Alterations of M2,3-muscarinic receptor protein and mRNA expression in the bladder of the fructose fed obese rat. *The Journal of urology*. 2007;178(4 Pt 1):1537-1542.
184. Braverman AS, Ruggieri MR, Sr. Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. *American journal of physiology Regulatory, integrative and comparative physiology*. 2003;285(3):R701-708.
185. Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, Bedretdinova DA, Ambühl D, Farag F, Lombardo R, Schneider MP, Burkhard FC. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. *European urology*. 2018;73(4):596-609.
186. Willis-Gray MG, Dieter AA, Geller EJ. Evaluation and management of overactive bladder: strategies for optimizing care. *Research and reports in urology*. 2016;8:113-122.
187. Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, Nazir J, Chapple C. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. *European urology*. 2018;74(3):324-333.

188. Ehlert FJ. Contractile role of M2 and M3 muscarinic receptors in gastrointestinal, airway and urinary bladder smooth muscle. *Life sciences*. 2003;74(2):355-366.
189. Togashi H, Emala CW, Hall IP, Hirshman CA. Carbachol-induced actin reorganization involves Gi activation of Rho in human airway smooth muscle cells. *The American journal of physiology*. 1998;274(5):L803-809.
190. Vogt A, Lutz S, Rumenapp U, Han L, Jakobs KH, Schmidt M, Wieland T. Regulator of G-protein signalling 3 redirects prototypical Gi-coupled receptors from Rac1 to RhoA activation. *Cellular signalling*. 2007;19(6):1229-1237.
191. Molnar PJ, Der B, Borsodi K, Balla H, Borbas Z, Molnar K, Ruisanchez E, Kenessey I, Horvath A, Keszthelyi A, Majoros A, Nyirady P, Offermanns S, Benyo Z. Isoprostanes evoke contraction of the murine and human detrusor muscle via activation of the thromboxane prostanoid TP receptor and Rho kinase. *Am J Physiol Renal Physiol*. 2021;320(4):F537-F547.
192. Hegde SS, Choppin A, Bonhaus D, Briaud S, Loeb M, Moy TM, Loury D, Eglen RM. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. *British journal of pharmacology*. 1997;120(8):1409-1418.
193. Matsui M, Griffin MT, Shehnaz D, Taketo MM, Ehlert FJ. Increased relaxant action of forskolin and isoproterenol against muscarinic agonist-induced contractions in smooth muscle from M2 receptor knockout mice. *The Journal of pharmacology and experimental therapeutics*. 2003;305(1):106-113.
194. Igawa Y, Zhang X, Nishizawa O, Umeda M, Iwata A, Taketo MM, Manabe T, Matsui M, Andersson KE. Cystometric findings in mice lacking muscarinic M2 or M3 receptors. *The Journal of urology*. 2004;172(6 Pt 1):2460-2464.
195. Moshirfar M, Parker L, Birdsong OC, Ronquillo YC, Hofstedt D, Shah TJ, Gomez AT, Hoopes PCS. Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature. *Medical hypothesis, discovery & innovation ophthalmology journal*. 2018;7(3):101-111.

## 9. Bibliography of the candidate's publications

### Publications related to the dissertation

**H. Balla**, K. Borsodi, P. Órsy, B. Horváth, P. J. Molnár, Á. Lénárt, M. Kosztelnik, É. Ruisanchez, J. Wess, S. Offermanns, P. Nyirády, and Z. Benyó, “Intracellular signaling pathways of muscarinic acetylcholine receptor-mediated detrusor muscle contractions”, *AMERICAN JOURNAL OF PHYSIOLOGY: RENAL PHYSIOLOGY*, vol. 325, pp. F618–F68, 2023. **IF: 4.200**

K. Borsodi, **H. Balla**, P. J. Molnár, Á. Lénárt, I. Kenessey, A. Horváth, A. Keszthelyi, M. Romics, A. Majoros, P. Nyirády, S. Offermanns, and Z. Benyó, “Signaling Pathways Mediating Bradykinin-Induced Contraction in Murine and Human Detrusor Muscle”, *FRONTIERS IN MEDICINE: GERIATRIC MEDICINE*, vol. 8, 2021. **IF: 3.900**

### Publications not related to the dissertation

P. J. Molnár, B. Dér, K. Borsodi, **H. Balla**, Z. Borbás, K. Molnár, É. Ruisanchez, I. Kenessey, A. Horváth, A. Keszthelyi, A. Majoros, P. Nyirády, S. Offermanns, and Z. Benyó, “Isoprostanes evoke contraction of the murine and human detrusor muscle via activation of the thromboxane prostanoid TP receptor and Rho kinase”, *AMERICAN JOURNAL OF PHYSIOLOGY: RENAL PHYSIOLOGY*, vol. 320, no. 4, pp. F537–F547, 2021. **IF: 4.097**

**Cumulative impact factor of the candidate's publication: 12.197**

## 10. Acknowledgments

I am very grateful to my mentor and supervisor, Professor Zoltán Benyó, for his guidance and encouragement. He has always made time for me, even at the expense of his free time during my PhD studies. I would like to thank him for his advice and for helping me in every possible way over the years, providing not only the infrastructure for the experiments but also consultations in a friendly but professional environment and opportunities to participate in scientific conferences in Hungary and abroad.

I am thankful to Péter Molnár, Kinga Borsodi and Ádám Lénárt for their efforts, support and help during the experiments and research work. I am grateful that we can work as a team.

I am very grateful to Éva Ruisanchez and Mónika Kosztelnik for their enormous help during the experiments, and for teaching me the methodology of quantification of activated RhoA and qPCR, respectively. I am also very grateful for their professional advices.

I am also very thankful to all the colleagues at the Department of Urology, Semmelweis University, for their help in obtaining urinary bladder samples for human studies.

I am very grateful to László Hricisák and Ágnes Fülöp for their help in managing the transgenic experimental animals, and to Ildikó Murányi for her excellent technical assistance during the laboratory work.

I would like to express my sincere gratitude to all my co-authors for their efforts and to all my colleagues, past and present, at the Institute of Translational Medicine.

Finally, I am very grateful to my husband, parents and family. Without their encouragement, inspiration and support, this thesis would not have been accomplished.